Page last updated: 2024-10-16

beta-alanine and Atrial Fibrillation

beta-alanine has been researched along with Atrial Fibrillation in 543 studies

Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.

Research Excerpts

ExcerptRelevanceReference
"Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)."10.27Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013)
"The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin."10.27Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013)
" In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with ≈80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation."9.19Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. ( Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S, 2014)
"We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban."9.19Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. ( Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC, 2014)
" Here we present a first comparison of complications after cardiac rhythm device (CRD) implantations in patients with atrial fibrillation (AF) treated with dabigatran or uninterrupted warfarin."9.19Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study. ( Bollmann, A; Breithardt, OA; Darma, A; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P, 2014)
"A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation."9.17Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013)
"In 18,113 AF patients in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, we used a previously developed method for integrating ischemic and bleeding events as "ischemic stroke equivalents" in order to compare a weighted benefit of 2 doses of dabigatran with each other, and with that of warfarin."9.17Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. ( Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S, 2013)
"3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death."9.17The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. ( Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J, 2013)
"We evaluated the effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure (HF) in the RE-LY trial."9.17Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. ( Brueckmann, M; Connolly, SJ; Ezekowitz, MD; Ferreira, J; Fraessdorf, M; Reilly, PA; Wallentin, L; Yusuf, S, 2013)
"Two new oral anticoagulants, rivaroxaban and dabigatran, with no need for anticoagulation monitoring, are available for patients with atrial fibrillation (AF)."9.17A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation. ( Ando, M; Hirayama, H; Kihara, Y; Nakano, Y; Sairaku, A; Yoshida, Y, 2013)
"To validate a patient decision aid (DA) for warfarin versus dabigatran, the first NOAC approved for atrial fibrillation (AF)."9.17Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. ( Curnew, G; Holbrook, A; Hong, C; Kim, S; Pullenayegum, E; Schulman, S, 2013)
"We aimed to evaluate the feasibility of an oral direct thrombin inhibitor, dabigatran, as a periprocedural anticoagulant for use with ablation of atrial fibrillation (AF)."9.17A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. ( Hirayama, H; Inden, Y; Kamiya, H; Murohara, T; Nanasato, M; Nin, T; Sairaku, A; Tatematsu, Y; Yoshida, Y, 2013)
"The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified."9.16Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012)
"Analysis of 18 113 participants with atrial fibrillation in the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial assigned to adjusted-dose warfarin (target international normalized ratio, 2-3) or dabigatran (150 mg or 110 mg, both twice daily)."9.16Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. ( Connolly, SJ; Diener, HC; Ezekowitz, MD; Hart, RG; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2012)
"Periprocedural anticoagulation using uninterrupted warfarin could reduce the risk of thromboembolic complications of atrial fibrillation (AF) ablation."9.16Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. ( Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E, 2012)
" The frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance."9.15Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. ( Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S, 2011)
"RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an international multicenter study (18,113 patients from 967 centers in 44 countries) that demonstrated the ability of dabigatran to reduce the occurrence of both stroke and hemorrhage in patients who had atrial fibrillation (AF) with high risks of stroke compared with patients who received warfarin."9.15Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. ( Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S, 2011)
"In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged <75 years."9.15Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. ( Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S, 2011)
"To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran."9.15Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011)
"Dabigatran etexilate, a new thrombin inhibitor, has been shown to be comparable to warfarin in patients with atrial fibrillation (AF)."8.90Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. ( Albenque, JP; Bouzeman, A; Boveda, S; Casteigt, B; Combes, N; Combes, S; Marijon, E; Narayanan, K; Providência, R, 2014)
"Pharmacogenetics-guided warfarin dosing is an alternative to standard clinical algorithms and new oral anticoagulants for patients with nonvalvular atrial fibrillation."8.90Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. ( Hughes, DA; Lane, S; Pink, J; Pirmohamed, M, 2014)
"In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and one or more defined risk factors."8.90{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. ( , 2014)
"Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation."8.90Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014)
"Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events."8.90Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014)
"Since the approval of dabigatran etexilate, numerous case reports have suggested the potential dangers of bleeding complications, especially given that there is no known antidote."8.90Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population. ( Brunetti, L; Chen, C; White, J, 2014)
" Treatment with dabigatran (220 mg per day) was initiated because of atrial fibrillation."8.90[Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature]. ( Inaishi, J; Mano, Y; Nogawa, S; Okada, S; Yoshizaki, T, 2014)
"Several studies have been conducted to study the efficacy and safety of rivaroxaban in the atrial fibrillation periprocedural ablation period with similar rates of thromboembolism and major bleeding risks compared with warfarin or dabigatran."8.90Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. ( Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A, 2014)
"Warfarin has remained the mainstay of stroke prevention in atrial fibrillation for the past 60 years."8.90Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation. ( Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P, 2014)
"The objective of this review was to compare the safety and efficacy of dabigatran, rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older adults."8.89Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly. ( Jeffery, SM; Ogbonna, KC, 2013)
"The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dabigatran etexilate (Boehringer Ingelheim Ltd, UK) to submit evidence for the clinical and cost-effectiveness of this drug for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) as part of the NICE single technology appraisal process."8.89Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal. ( Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N, 2013)
"The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation."8.89Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013)
"Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)."8.89Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013)
"The safety and efficacy of dabigatran in the periprocedural period for patients undergoing atrial fibrillation ablation is not well established."8.89Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. ( Crystal, E; Danon, A; Healey, JS; Kansal, N; Lashevsky, I; Morillo, CA; Newman, D; Schulman, S; Shurrab, M, 2013)
"Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation."8.88Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012)
"Oral anticoagulation with vitamin K antagonists (warfarin, phenprocoumon) is successful in both primary and secondary stroke prevention in patients with atrial fibrillation, yielding a 60-70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26%."8.88Stroke prevention in atrial fibrillation: do we still need warfarin? ( Diener, HC; Hohnloser, SH; Lip, GY; Weber, R, 2012)
"To critically assess current evidence regarding the cost effectiveness of dabigatran for preventing stroke in patients with NVAF compared with warfarin."8.88Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. ( Adcock, AK; Aguilar, MI; Demaerschalk, BM; Hoffman-Snyder, CR; Lee-Iannotti, JK; Wellik, KE; Wingerchuk, DM, 2012)
"For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR."8.88Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012)
"In the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial, dabigatran 150 mg was shown to be superior to warfarin for the prevention of stroke or systemic embolism."8.88Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. ( DiNicolantonio, JJ, 2012)
"New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients with atrial fibrillation (AF)."8.88Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. ( Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A, 2012)
"New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation."8.88An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012)
"A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation."8.88Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. ( Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C, 2012)
"In patients with NVAF at risk of stroke, the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial demonstrated that, compared with warfarin, dabigatran 150 mg b."8.88New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. ( Barrios, V; Escobar, C, 2012)
"Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF)."8.87Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2011)
" The recently introduced oral direct thrombin antagonist, dabigatran, has been shown in phase III clinical trials to be noninferior in efficacy to warfarin for the prevention of thromboembolic events in patients with atrial fibrillation, as well as in treatment of acute venous thromboembolism."8.87Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. ( Acharjee, S; Cannon, CP, 2011)
"The objective of this review is to summarize data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trials of apixaban for stroke prevention in patients with atrial fibrillation (AF)."8.87Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. ( Yates, SW, 2011)
"A Markov decision analysis model was developed to compare dabigatran (110 or 150 mg twice a day) to warfarin titrated to target prothrombin time in patients with NVAF at high risk of stroke."8.12Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India. ( Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR, 2022)
"The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established."7.81Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015)
"It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice."7.81Risk of bleeding with dabigatran in atrial fibrillation. ( Baik, SH; Hernandez, I; Piñera, A; Zhang, Y, 2015)
" We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy."7.81Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015)
"Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation."7.81Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. ( Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015)
"Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation."7.81Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ( Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB, 2015)
" She had been on dabigatran for 13 months due to atrial fibrillation and arterial hypertension."7.81[Exfoliative esophagitis while taking dabigatran]. ( Meesmann, M; Scheppach, W, 2015)
"Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in patients with atrial fibrillation."7.81Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. ( Fujino, T; Kuwahara, T; Nakajima, J; Nakashima, E; Okubo, K; Takagi, K; Takahashi, A; Takigawa, M; Tsutsui, H; Watari, Y; Yamao, K, 2015)
"Bleeding and thromboembolic events during the periprocedural period were evaluated in 363 consecutive patients who underwent CA for AF at Nagoya University Hospital, and received uninterrupted dabigatran (n=173) or uninterrupted warfarin (n=190) for periprocedural anticoagulation."7.81Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. ( Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015)
"Dabigatran is an oral thrombin inhibitor which has been approved for prevention of stroke or embolism in atrial fibrillation patients as an alternative to vitamin K antagonists."7.80Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. ( Finsterer, J; Krutisch, G; Stöllberger, C, 2014)
"Dabigatran may provide less protection against myocardial infarction than vitamin K antagonists (VKAs) in patients with atrial fibrillation."7.80Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014)
"Acute ischemic stroke thrombolysis in patients taking dabigatran is controversial because of a presumed increased risk of symptomatic hemorrhagic transformation."7.80Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. ( Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A, 2014)
"Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF)."7.80Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H, 2014)
"Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous."7.80Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014)
"By using nationwide Danish prescription and patient registries, we identified 11,315 first-time dabigatran users with atrial fibrillation."7.80Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. ( Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014)
"We report a case of life-threatening haemoptysis after administration of dabigatran in a patient with bronchiectasis."7.80Massive haemoptysis following dabigatran administration in a patient with bronchiectasis. ( Hayama, M; Inoue, H; Mio, T; Wada, H, 2014)
"Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported."7.80Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014)
"Dabigatran is an oral anticoagulant from the class of the direct thrombin inhibitors, indicated for prevention of thromboembolic events in patients with non valvular atrial fibrillation."7.80[Hemodialysis to remove anticoagulant dabigatran during emergencies]. ( Campbell, S; Carrizo, A, 2014)
"To conduct an economic evaluation of the currently prescribed treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin, aspirin, and novel oral anticoagulants (NOACs) from a French payer perspective."7.80Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. ( Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T, 2014)
"In randomized trials, patients with atrial fibrillation (AF) receiving dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than those on warfarin."7.80Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. ( Alonso, A; Bengtson, LG; Chen, LY; Lakshminarayan, K; Lutsey, PL; MacLehose, RF, 2014)
"This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥ 75), and the overall population (All) from a US Medicare payer perspective."7.80Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. ( Brand, S; Brueckmann, M; Clemens, A; Kansal, A; Lim, J; Noack, H; Peng, S; Sander, S; Sorensen, S, 2014)
"Clinical trial data suggest that dabigatran and warfarin have similar rates of major bleeding but higher rates of gastrointestinal bleeding."7.80Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014)
" The purpose of this study was to estimate the change in medical costs related to stroke and major bleeding for each NOAC (apixaban, dabigatran, and rivoraxaban) relative to warfarin in a RW NVAF population."7.80Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. ( Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N, 2014)
"The oral direct thrombin inhibitor dabigatran is increasingly used to prevent thromboembolic stroke in patients with atrial fibrillation (AF)."7.80On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. ( Antovic, JP; Beck, O; Eintrei, J; Hjemdahl, P; Malmström, RE; Muhrbeck, J; Pohanka, A; Rönquist-Nii, Y; Skeppholm, M, 2014)
" New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke."7.80[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014)
"This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin."7.80Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014)
"This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore."7.80Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. ( Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F, 2014)
"Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation."7.80A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. ( Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R, 2014)
"We report a case of a patient receiving dabigatran who developed a life-threatening bleeding complication during cardiac ablation that rapidly resolved after administration of Factor Eight Inhibitor Bypassing Activity (FEIBA)."7.79Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. ( Dager, WE; Gosselin, RC; Roberts, AJ, 2013)
"To compare the management cost and cost-effectiveness of dabigatran with warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' perspectives."7.79Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital. ( Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM, 2013)
"Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AF)."7.79Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. ( Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP, 2013)
"It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors."7.79[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013)
"To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin."7.79Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. ( Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE, 2013)
"Uninterrupted oral anticoagulant (OA) therapy with warfarin has become the standard of care at many centers performing catheter ablation of atrial fibrillation (AF)."7.79Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. ( Doppalapudi, H; Gunter, A; Kay, GN; Maddox, W; McElderry, HT; Osorio, J; Plumb, VJ; Yamada, T, 2013)
"Dabigatran is effective for both the prevention of stroke and bleeding in patients with atrial fibrillation (AF)."7.79Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. ( Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013)
"The use of dabigatran would lead to a significant reduction of strokes and deaths attributable to AF in France."7.79Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation. ( Chevalier, J; de Pouvourville, G; Giroud, M, 2013)
"A number of models exploring the cost-effectiveness of dabigatran versus warfarin for stroke prevention in atrial fibrillation have been published."7.79A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. ( Bradley-Kennedy, C; Kansal, AR; Monz, BU; Peng, S; Sorensen, SV, 2013)
"Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness."7.79Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013)
"In patients undergoing left atrial catheter ablation for AF or left atrial flutter, use of periprocedural dabigatran etexilate provides a safe and effective anticoagulation strategy compared to warfarin."7.79Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. ( Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP, 2013)
" We evaluated the influence of the putative etiological variables and the bleeding score, HAS-BLED score, on APTT values: age greater than 70 years, renal function, gender, dose of dabigatran, and the concomitant prescription of a P-glycoprotein inhibitor."7.79Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y, 2013)
"Percutaneous left atrial appendage (LAA) occlusion and novel pharmacological therapies are now available to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effectiveness of LAA occlusion compared with dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown."7.79Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. ( Micieli, A; Singh, SM; Wijeysundera, HC, 2013)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."7.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran, and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation (NVAF) patients."7.79Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. ( Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D, 2013)
"Cerebral microthromboembolism after atrial fibrillation (AF) ablation has been reported in 4-20% with perioperative warfarin."7.79The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. ( Hamasaki, S; Ichiki, H; Iriki, Y; Ishida, S; Maenosono, R; Miyata, M; Namino, F; Ninomiya, Y; Oketani, N; Okui, H; Tei, C, 2013)
"Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding."7.79Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"In an 89-year-old female with atrial fibrillation dabigatran had been started 11 days before admission, following a transitory ischemic attack."7.79Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy. ( Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C, 2013)
" Six months before presentation, the patient was placed on Dabigatran etexilate (Dabigatran) (110 mg BID) for atrial fibrillation."7.79The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. ( Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A, 2013)
"Dabigatran is a recently introduced direct thrombin inhibitor licensed for use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation."7.79Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. ( Boga, T; Michel, J; Mundell, D; Sasse, A, 2013)
"It is not clear whether dabigatran is as safe and effective as uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF)."7.79Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. ( Bogun, F; Carrigan, T; Chugh, A; Crawford, T; Ghanbari, H; Good, E; Jongnarangsin, K; Kennedy, R; Kim, JS; Latchamsetty, R; Morady, F; Oral, H; Pelosi, F; Saint-Phard, W; She, F; Sinno, M; Suwanagool, A; Yokokawa, M, 2013)
"Dabigatran, administered orally as the prodrug dabigatran etexilate (DE), is a direct thrombin inhibitor shown to be effective in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF)."7.78Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. ( Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012)
"The concept of net clinical benefit has been used to quantify the balance between risk of ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral anticoagulant therapy (OAC) in the setting of non-valvular atrial fibrillation (AF), and has shown that patients at highest risk of stroke and thromboembolism gain the greatest benefit from OAC with warfarin."7.78Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. ( Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C, 2012)
"To present a case of dabigatran use for nonvalvular atrial fibrillation in a patient from a population for whom it has not been studied."7.78Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies. ( Fieland, D; Taylor, M, 2012)
"Dabigatran is a new oral anticoagulant recently approved for the prevention of stroke or systemic embolism in patients with atrial fibrillation (AF)."7.78Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. ( Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012)
"In patients undergoing AF ablation, periprocedural dabigatran use significantly increases the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy."7.78Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012)
"The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed."7.78Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Easton, JD; Johnston, SC; Kamel, H; Kim, AS, 2012)
" Based on various everyday situations in clinical routine, the purpose of the present expert recommendations is to provide appropriate perioperative and periinterventional management for patients with atrial fibrillation undergoing long-term treatment with the thrombin inhibitor dabigatran."7.78Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. ( Brodmann, M; Domanovits, H; Eber, B; Gottsauner-Wolf, M; Halbmayer, WM; Hiesmayr, JM; Kyrle, PA; Längle, F; Roithinger, FX; Watzke, H; Weltermann, A; Windhager, R; Wolf, C; Zweiker, R, 2012)
"Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation."7.78Dabigatran for stroke prevention in atrial fibrillation. ( Diener, HC; Hohnloser, SH, 2012)
"Dabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal."7.78Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. ( Cheng, G; Tsui, KK; Wong, RS; You, JH, 2012)
"This case report describes agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a 70-year-old woman with paroxysmal atrial fibrillation (AF)."7.78Agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation. ( Hayashi, H; Horie, M; Kitoh, K; Mitsunami, K, 2012)
"In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran."7.78A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012)
"Canadian patients with atrial fibrillation (AF) in whom anticoagulation is appropriate have two new choices for anticoagulation for prevention of stroke and systemic embolism--dabigatran etexilate (dabigatran) and rivaroxaban."7.78Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. ( Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV, 2012)
"Assessment of the cost-effectiveness of dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain, from the perspective of the National Health System."7.78Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. ( Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC, 2012)
"Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin."7.78Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. ( Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM, 2012)
"Warfarin, at a dose adjusted according to the INR, is the standard prophylactic anticoagulant for patients with atrial fibrillation and a major risk of thrombosis."7.78Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran. ( , 2012)
"To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF."7.77Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011)
"Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent."7.77Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. ( Gage, BF; Shah, SV, 2011)
"The central pharmacologic approach to stroke prevention in atrial fibrillation has recently changed with the approval of dabigatran by the US Food and Drug Administration (FDA)."7.77Dabigatran in atrial fibrillation: pharmacology and clinical trials. ( Ezekowitz, MD; Nagarakanti, R, 2011)
"To report an incident of a drug-induced exanthem during treatment with dabigatran in a patient without prior exposure to the drug."7.77Drug-induced exanthem following dabigatran. ( Blais, DM; Boyd, JM; Hummel, J; Whitehead, H, 2011)
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared."6.79Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014)
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms."6.79[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014)
"Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit."6.78Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. ( Davidson, T; Husberg, M; Janzon, M; Levin, LÅ; Oldgren, J, 2013)
"Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been developed as an alternative to vitamin K antagonists (VKAs)."6.50Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014)
" However, in elderly patients with impaired renal function or considerable bleeding risks, label advice regarding dosing needs strict observation."6.50Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. ( Harder, S; Meyer Dos Santos, S, 2014)
"Ischemic stroke is a severe complication of AF often resulting in disability or death."6.50[The use of dabigatran for prevention of ischemic stroke in patiets with atrial fibrillation: special features of treatment in different clinical situations]. ( Shchendrygina, AA, 2014)
"Stroke is the most feared complication among patients with atrial fibrillation."6.49Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. ( Lopes, RD; Newby, LK; Truffa, AA, 2013)
"Dabigatran was the first of the agents to be widely available, and in the RE-LY study, dabigatran (150 mg dose) showed superiority to warfarin in preventing ischemic stroke and a significant reduction in intracranial bleeding."6.49New alternative anticoagulants in atrial fibrillation: the move beyond warfarin. ( Bhimani, AA; Hong, M, 2013)
"NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin."6.49[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013)
"Dabigatran is a direct thrombin (factor IIa) inhibitor that overcomes many of the limitations associated with warfarin."6.48Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation. ( Ibayashi, S; Matsumoto, M; Nagao, T; Nagata, K; Nakagawara, J; Tanahashi, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yasaka, M, 2012)
"Dabigatran is an oral direct thrombin inhibitor."6.48[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation]. ( Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A, 2012)
" The vitamin K antagonist warfarin has traditionally been used in these patients but presents challenges in dosing and monitoring in these patients."6.47Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. ( Baker, WL; Bendel, SD; Bona, R, 2011)
"Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)."6.27Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013)
"The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin."6.27Management and outcomes of major bleeding during treatment with dabigatran or warfarin. ( Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S, 2013)
"Dabigatran was administrated twice daily in a two dose regimens: 150 mg (5 patients) and 110 mg (14 patients)."5.42Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ( Dobrotová, M; Galajda, P; Ivanková, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2015)
"Warfarin-related intracerebral hemorrhage carries a particularly high risk of neurologic deterioration and death because of a high rate of hematoma expansion of about 50%."5.40Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion. ( Damgaard, D; Simonsen, CZ; Steiner, T; Tietze, A, 2014)
" The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial."5.40A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. ( Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014)
"Direct-current cardioversion (DCCV) for persistent atrial fibrillation or atrial flutter (AF) carries a risk of thromboembolic events (TEs)."5.40Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. ( Groh, C; Passman, R; Yadlapati, A, 2014)
"Dabigatran is a new oral anticoagulant that does not require INR monitoring."5.39Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. ( Eichler, K; Plessow, R; Pletscher, M; Wieser, S, 2013)
"Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events."5.38The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)
"Dabigatran is a direct thrombin inhibitor, acting like other members in its class (bivalirudin, argatroban) to impede the clotting process through selective and reversible binding with both free and clot-bound thrombin."5.38Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. ( Boniface, K; Moore, CH; Scott, J; Snashall, J, 2012)
" In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) trial, dabigatran, with ≈80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation."5.19Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. ( Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S, 2014)
"We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban."5.19Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. ( Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC, 2014)
" Here we present a first comparison of complications after cardiac rhythm device (CRD) implantations in patients with atrial fibrillation (AF) treated with dabigatran or uninterrupted warfarin."5.19Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study. ( Bollmann, A; Breithardt, OA; Darma, A; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P, 2014)
"A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation."5.17Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. ( Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E, 2013)
"In 18,113 AF patients in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, we used a previously developed method for integrating ischemic and bleeding events as "ischemic stroke equivalents" in order to compare a weighted benefit of 2 doses of dabigatran with each other, and with that of warfarin."5.17Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. ( Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S, 2013)
"3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death."5.17The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. ( Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J, 2013)
"We evaluated the effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure (HF) in the RE-LY trial."5.17Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. ( Brueckmann, M; Connolly, SJ; Ezekowitz, MD; Ferreira, J; Fraessdorf, M; Reilly, PA; Wallentin, L; Yusuf, S, 2013)
"The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group."5.17Dabigatran versus warfarin in patients with mechanical heart valves. ( Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU, 2013)
"Two new oral anticoagulants, rivaroxaban and dabigatran, with no need for anticoagulation monitoring, are available for patients with atrial fibrillation (AF)."5.17A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation. ( Ando, M; Hirayama, H; Kihara, Y; Nakano, Y; Sairaku, A; Yoshida, Y, 2013)
"To validate a patient decision aid (DA) for warfarin versus dabigatran, the first NOAC approved for atrial fibrillation (AF)."5.17Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation. ( Curnew, G; Holbrook, A; Hong, C; Kim, S; Pullenayegum, E; Schulman, S, 2013)
"Among patients given dabigatran for atrial fibrillation, NB-UGI AEs are generally mild or moderate; 4% stopped taking the drug over a median of 21."5.17Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. ( Aisenberg, J; Bytzer, P; Connolly, SJ; Ezekowitz, M; Formella, S; Reilly, PA; Yang, S, 2013)
"We aimed to evaluate the feasibility of an oral direct thrombin inhibitor, dabigatran, as a periprocedural anticoagulant for use with ablation of atrial fibrillation (AF)."5.17A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. ( Hirayama, H; Inden, Y; Kamiya, H; Murohara, T; Nanasato, M; Nin, T; Sairaku, A; Tatematsu, Y; Yoshida, Y, 2013)
"The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified."5.16Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. ( Aizawa, T; Funada, R; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Uejima, T; Yajima, J; Yamashita, T, 2012)
"Analysis of 18 113 participants with atrial fibrillation in the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial assigned to adjusted-dose warfarin (target international normalized ratio, 2-3) or dabigatran (150 mg or 110 mg, both twice daily)."5.16Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. ( Connolly, SJ; Diener, HC; Ezekowitz, MD; Hart, RG; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2012)
"Periprocedural anticoagulation using uninterrupted warfarin could reduce the risk of thromboembolic complications of atrial fibrillation (AF) ablation."5.16Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. ( Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E, 2012)
" The frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance."5.15Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. ( Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S, 2011)
"RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an international multicenter study (18,113 patients from 967 centers in 44 countries) that demonstrated the ability of dabigatran to reduce the occurrence of both stroke and hemorrhage in patients who had atrial fibrillation (AF) with high risks of stroke compared with patients who received warfarin."5.15Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. ( Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S, 2011)
"In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged <75 years."5.15Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. ( Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S, 2011)
"To evaluate the prognostic importance of CHADS(2) risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran."5.15Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. ( Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S, 2011)
"The objective of this analysis was to test the equivalence of three NOACs (dabigatran, rivaroxaban, apixaban) in orthopedic surgery and four NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) in non-valvular atrial fibrillation."4.91Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation. ( Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S, 2015)
" They are effective and safe compared to warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation and for the treatment of venous thromboembolism, and they are comparable to low-molecular-weight heparin for thromboprophylaxis after hip or knee arthroplasty."4.91Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? ( Arepally, GM; Ortel, TL, 2015)
"Dabigatran etexilate, a new thrombin inhibitor, has been shown to be comparable to warfarin in patients with atrial fibrillation (AF)."4.90Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. ( Albenque, JP; Bouzeman, A; Boveda, S; Casteigt, B; Combes, N; Combes, S; Marijon, E; Narayanan, K; Providência, R, 2014)
"Pharmacogenetics-guided warfarin dosing is an alternative to standard clinical algorithms and new oral anticoagulants for patients with nonvalvular atrial fibrillation."4.90Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. ( Hughes, DA; Lane, S; Pink, J; Pirmohamed, M, 2014)
" Three non-VKA oral anticoagulants (OACs), dabigatran, rivaroxaban and apixaban, are available for the prevention of stroke in patients with atrial fibrillation (AF) and may change clinical practice."4.90Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. ( Barillari, G; Cheng, JW, 2014)
"In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and one or more defined risk factors."4.90{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. ( , 2014)
"Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation."4.90Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014)
"Dabigatran is a novel oral anticoagulant and may be useful during atrial fibrillation (AF) ablation for prevention of thromboembolic events."4.90Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. ( Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J, 2014)
"Four recently introduced new oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) have been shown to be at least as efficacious and safe as warfarin for stroke prevention in patients with atrial fibrillation in their respective trials."4.90New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. ( Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS, 2014)
"Dabigatran, a direct thrombin inhibitor and 2 factor Xa inhibitors, rivaroxaban and apixaban, are target-specific oral anticoagulants (TSOACs) approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)."4.90Practical aspects of new oral anticoagulant use in atrial fibrillation. ( Crowther, M; Pasierski, T; Undas, A; Windyga, J, 2014)
"Since the approval of dabigatran etexilate, numerous case reports have suggested the potential dangers of bleeding complications, especially given that there is no known antidote."4.90Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population. ( Brunetti, L; Chen, C; White, J, 2014)
" Treatment with dabigatran (220 mg per day) was initiated because of atrial fibrillation."4.90[Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature]. ( Inaishi, J; Mano, Y; Nogawa, S; Okada, S; Yoshizaki, T, 2014)
"Several studies have been conducted to study the efficacy and safety of rivaroxaban in the atrial fibrillation periprocedural ablation period with similar rates of thromboembolism and major bleeding risks compared with warfarin or dabigatran."4.90Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. ( Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A, 2014)
"Warfarin has remained the mainstay of stroke prevention in atrial fibrillation for the past 60 years."4.90Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation. ( Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P, 2014)
"The availability of 4 non-vitamin K oral anticoagulants (NOACs), that is, dabigatran, rivaroxaban, apixaban, and edoxaban, has changed the landscape of stroke prevention in patients with atrial fibrillation."4.90Oral anticoagulants for stroke prevention in atrial fibrillation. ( Lane, DA; Lip, GY; Senoo, K, 2014)
" Dabigatran, rivaroxaban, apixaban, and edoxaban have been shown to be as effective as warfarin in the treatment and prevention of venous thromboembolism and prevention of stroke in nonvalvular atrial fibrillation."4.90Target-specific oral anticoagulants: practice issues for the clinician. ( Giugliano, RP; Plitt, A, 2014)
"All NOACs are at least as effective as warfarin for stroke prevention in patients with nonvalvular AF, and are at least as safe in terms of bleeding risk according to 3 large trials."4.90Approach to the new oral anticoagulants in family practice: part 1: comparing the options. ( Bell, AD; Douketis, J; Eikelboom, J; Liew, A, 2014)
"The objective of this review was to compare the safety and efficacy of dabigatran, rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older adults."4.89Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly. ( Jeffery, SM; Ogbonna, KC, 2013)
"The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of dabigatran etexilate (Boehringer Ingelheim Ltd, UK) to submit evidence for the clinical and cost-effectiveness of this drug for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) as part of the NICE single technology appraisal process."4.89Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal. ( Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N, 2013)
"Dabigatran was the first of a new generation of anticoagulation drugs for the indication of non-valvular atrial fibrillation (AF) to be approved."4.89Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide. ( Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD, 2013)
"Dabigatran is an oral, direct, and competitive inhibitor of thrombin, which is administered to patients with non-valvular atrial fibrillation for prevention of stroke at a dose of 110 mg twice daily or 150 mg twice daily."4.89[Direct oral thrombin inhibitor, "dabigatran"]. ( Yasaka, M, 2013)
"Dabigatran is a direct thrombin inhibitor gaining popularity as a stroke prevention agent in patients with atrial fibrillation."4.89Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature. ( Abel, TJ; Greenlee, JD; Grossbach, A; Howard, MA; Jackson, AW; Viljoen, SV; Wassef, SN, 2013)
"Warfarin has been the mainstay oral anticoagulant (OAC) medication prescribed for stroke prevention in atrial fibrillation (AF) patients."4.89Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. ( Gong, IY; Kim, RB, 2013)
"The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation."4.89Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013)
"Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF)."4.89Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. ( Alexander, JH; Atwater, BD; Bahnson, TD; Daubert, JP; Hasselblad, V; Piccini, JP; Steinberg, BA; Washam, JB, 2013)
" The US Food and Drug Administration recently approved 2 new oral anticoagulants, dabigatran and rivaroxaban, for stroke prevention in patients with atrial fibrillation, and is currently reviewing a drug application for a third new oral anticoagulant, apixaban."4.89Novel oral anticoagulants: a review of new agents. ( Wanat, MA, 2013)
"In patients with atrial fibrillation (AF) oral anticoagulation with vitamin-K antagonists (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention yielding a 60-70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26 percent."4.89Novel oral anticoagulants in secondary prevention of stroke. ( Diener, HC; Easton, JD; Hankey, GJ; Hart, RG, 2013)
"The safety and efficacy of dabigatran in the periprocedural period for patients undergoing atrial fibrillation ablation is not well established."4.89Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. ( Crystal, E; Danon, A; Healey, JS; Kansal, N; Lashevsky, I; Morillo, CA; Newman, D; Schulman, S; Shurrab, M, 2013)
"Dabigatran has been associated with greater risk of myocardial infarction (MI) than warfarin."4.89Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. ( Artang, R; Nielsen, JD; Rome, E; Vidaillet, HJ, 2013)
"Indications for use of the new anticoagulants include thromboprophylaxis after total hip and knee replacement surgery (all three), prevention of stroke and systemic embolism in non-valvular atrial fibrillation (all three), treatment of acute venous thrombosis and secondary prophylaxis after venous thrombosis (currently only rivaroxaban)."4.89New oral anticoagulants--a review. ( Atar, D; Ghanima, W; Sandset, PM, 2013)
"Oral anticoagulant therapy, either with vitamin K antagonists (VKAs) or with novel oral anticoagulants such as dabigatran, rivaroxaban, and apixaban, is the mainstay for thromboprophylaxis in patients with atrial fibrillation (AF)."4.89Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. ( Kornej, J; Lip, GY; Potpara, T, 2013)
"Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF)."4.89[Evidence of novel oral anticoagulants (NOAC)]. ( Kitazono, T, 2013)
"The novel oral anticoagulant drugs, comprising dabigatran, rivaroxaban, and apixaban, have emerged as compelling alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation, and low‑molecular‑weight heparin for thromboprophylaxis following hip and knee arthroplasty."4.89Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials. ( Darvish-Kazem, S; Douketis, JD; Liew, A, 2013)
" We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban."4.89The novel anticoagulants: the surgeons' prospective. ( Martin, EN; Money, SR; Shamoun, FE, 2013)
"Dabigatran and rivaroxaban are novel anticoagulants that have been approved for the prevention of thromboembolic events in atrial fibrillation."4.89Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. ( Brem, E; Foran, M; Koyfman, A, 2013)
"Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation."4.88Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012)
"Randomized clinical trials have conclusively demonstrated that warfarin prevents stroke in patients with atrial fibrillation."4.88Promise of factor Xa inhibition in atrial fibrillation. ( Al-Khatib, SM; Alexander, JH; Granger, CB; Lopes, RD; Mahaffey, KW; Patel, MR, 2012)
"Oral anticoagulation with vitamin K antagonists (warfarin, phenprocoumon) is successful in both primary and secondary stroke prevention in patients with atrial fibrillation, yielding a 60-70% relative reduction in stroke risk compared with placebo, as well as a mortality reduction of 26%."4.88Stroke prevention in atrial fibrillation: do we still need warfarin? ( Diener, HC; Hohnloser, SH; Lip, GY; Weber, R, 2012)
" This paper reviews the role of the novel anticoagulants, dabigatran, rivaroxaban and apixaban, in stroke prevention among patients with nonvalvular atrial fibrillation."4.88Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. ( Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ, 2012)
"Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF)."4.88ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? ( Parma, Z; Syzdół, M; Tendera, M, 2012)
"To critically assess current evidence regarding the cost effectiveness of dabigatran for preventing stroke in patients with NVAF compared with warfarin."4.88Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. ( Adcock, AK; Aguilar, MI; Demaerschalk, BM; Hoffman-Snyder, CR; Lee-Iannotti, JK; Wellik, KE; Wingerchuk, DM, 2012)
"For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR."4.88Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012)
"In the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial, dabigatran 150 mg was shown to be superior to warfarin for the prevention of stroke or systemic embolism."4.88Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. ( DiNicolantonio, JJ, 2012)
"New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients with atrial fibrillation (AF)."4.88Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. ( Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A, 2012)
"New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation."4.88An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. ( Ansell, J; Mantha, S, 2012)
"A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation."4.88Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. ( Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C, 2012)
"In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation."4.88Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2012)
"In patients with atrial fibrillation (AF) warfarin has been the mainstay therapy for stroke prevention."4.88Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. ( Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH, 2012)
" Dabigatran, does not require dose-adjustment and appears to be more effective at reducing the risk of stroke with similar risks of bleeding in patients with atrial fibrillation (AF)."4.88Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison. ( Alonso-Coello, P; Guyatt, G; Zhou, Q, 2012)
" The factor Xa inhibitor, rivaroxaban, has shown promising results in the treatment of acute coronary syndrome but is not yet approved for that indication."4.88What did we learn from new oral anticoagulant treatment? ( Esmon, CT, 2012)
"We present data on possibility of anticoagulant therapy in conjunction with electrical cardioversion in patients with atrial fibrillation using novel anticoagulant - dabigatran - and a case of successful lysis of thrombus in the left ventricular cavity at the background of its administration."4.88[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation]. ( Dovgalevskiĭ, IaP; Furman, NV; Kuvshinova, LE, 2012)
"In patients with NVAF at risk of stroke, the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial demonstrated that, compared with warfarin, dabigatran 150 mg b."4.88New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. ( Barrios, V; Escobar, C, 2012)
"Warfarin has been the effective treatment in the prophylaxis of cardioembolism, in particular in patients with atrial fibrillation, for more than 50 years."4.87[Thromboembolic prophylaxis 2011: is warfarin on the wane?]. ( Di Pasquale, G; Riva, L, 2011)
"Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF)."4.87Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). ( Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A, 2011)
" The recently introduced oral direct thrombin antagonist, dabigatran, has been shown in phase III clinical trials to be noninferior in efficacy to warfarin for the prevention of thromboembolic events in patients with atrial fibrillation, as well as in treatment of acute venous thromboembolism."4.87Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. ( Acharjee, S; Cannon, CP, 2011)
"The objective of this review is to summarize data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trials of apixaban for stroke prevention in patients with atrial fibrillation (AF)."4.87Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. ( Yates, SW, 2011)
"Long-term anticoagulation with a vitamin K antagonist (VKA) or the new agent dabigatran is recommended to decrease stroke risk in patients with atrial fibrillation."4.87Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies. ( Garwood, CL; Hwang, JM; Moser, LR, 2011)
"Randomized trials have demonstrated that warfarin is effective for stroke prevention in patients with atrial fibrillation (AF), yielding relative risk reductions for ischemic stroke of nearly 70%."4.86New options for stroke prevention in atrial fibrillation. ( Cannon, CP; Stecker, EC, 2010)
"A Markov decision analysis model was developed to compare dabigatran (110 or 150 mg twice a day) to warfarin titrated to target prothrombin time in patients with NVAF at high risk of stroke."4.12Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India. ( Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR, 2022)
"The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established."3.81Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. ( Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R, 2015)
"It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice."3.81Risk of bleeding with dabigatran in atrial fibrillation. ( Baik, SH; Hernandez, I; Piñera, A; Zhang, Y, 2015)
" We investigated the risks of ischemic stroke and intracranial hemorrhage (ICH) in relation to warfarin at various TTRs in a real-world cohort of Chinese patients with atrial fibrillation receiving warfarin and compared with those on dabigatran, aspirin, and no therapy."3.81Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. ( Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY, 2015)
"Although dabigatran, an oral direct thrombin inhibitor, does not require routine monitoring, high plasma concentration of dabigatran (PDC) at trough level is shown to be a high risk for bleeding in patients with nonvalvular atrial fibrillation (NVAF)."3.81CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. ( Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Okumura, K; Owada, S; Sasaki, K; Sasaki, S; Tomita, H, 2015)
"Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation."3.81Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. ( Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015)
"Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation."3.81Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. ( Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB, 2015)
"A report has demonstrated that in patients with atrial fibrillation the novel oral anticoagulant, dabigatran, increases the risk of gastrointestinal bleeding by nearly twofold compared with warfarin."3.81Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants. ( Rockey, DC, 2015)
"Novel oral anticoagulants are available for the management of atrial fibrillation and are considered more convenient to use than warfarin."3.81Patterns of oral anticoagulants use in atrial fibrillation. ( Beauchesne, M; Blais, L; Brais, C; Farand, P; Larochelle, J; Letemplier, G; Perreault, S; Tousignant, A; Turgeon, M, 2015)
"The objectives of this national chart audit (January to June 2013) of 6,346 patients with atrial fibrillation (AF; ≥18 years without a significant heart valve disorder) from 647 primary care physicians were to (1) describe the frequency of stroke and bleed risk assessments in patients with nonvalvular AF by primary care physicians, including the accuracy of these assessments relative to established predictive indexes; (2) outline contemporary methods of anticoagulation used; and (3) report the time in the therapeutic range among patients prescribed warfarin."3.81Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit). ( Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH, 2015)
" She had been on dabigatran for 13 months due to atrial fibrillation and arterial hypertension."3.81[Exfoliative esophagitis while taking dabigatran]. ( Meesmann, M; Scheppach, W, 2015)
" A total of 67 Veterans Health Administration sites with 20 or more patients filling dabigatran prescriptions between 2010 and 2012 for nonvalvular atrial fibrillation were sampled (4863 total patients; median, 51 patients per site)."3.81Site-level variation in and practices associated with dabigatran adherence. ( Carey, EP; Cunningham, F; Glorioso, TJ; Ho, PM; Jackevicius, C; Lambert-Kerzner, A; Longo, L; Rose, A; Shore, S; Turakhia, MP, 2015)
"Incidence rates (events/100 patient years) and propensity score matched Cox proportional hazards models were used to estimate rates of total gastrointestinal bleeds, upper gastrointestinal bleeds, and lower gastrointestinal bleeds for the novel oral anticoagulants compared with warfarin in patients with and without atrial fibrillation."3.81Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. ( Abraham, NS; Alexander, GC; Crown, W; Haas, LR; Heien, H; Shah, ND; Singh, S, 2015)
"Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in patients with atrial fibrillation."3.81Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation. ( Fujino, T; Kuwahara, T; Nakajima, J; Nakashima, E; Okubo, K; Takagi, K; Takahashi, A; Takigawa, M; Tsutsui, H; Watari, Y; Yamao, K, 2015)
"Bleeding and thromboembolic events during the periprocedural period were evaluated in 363 consecutive patients who underwent CA for AF at Nagoya University Hospital, and received uninterrupted dabigatran (n=173) or uninterrupted warfarin (n=190) for periprocedural anticoagulation."3.81Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. ( Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015)
"Dabigatran is an oral thrombin inhibitor which has been approved for prevention of stroke or embolism in atrial fibrillation patients as an alternative to vitamin K antagonists."3.80Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. ( Finsterer, J; Krutisch, G; Stöllberger, C, 2014)
"In the RE-LY trial dabigatran 150 mg twice daily (D150) showed significantly fewer strokes, and 110 mg (D110) significantly fewer major bleeding events (MBE) compared to well-controlled warfarin in patients with atrial fibrillation (AF)."3.80Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. ( Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S, 2014)
"Dabigatran may provide less protection against myocardial infarction than vitamin K antagonists (VKAs) in patients with atrial fibrillation."3.80Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014)
"Dabigatran is a direct thrombin inhibitor indicated for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation."3.80[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. ( Bachellerie, B; Conil, JM; Crognier, L; Fourcade, O; Georges, B; Ruiz, S; Seguin, T, 2014)
"Acute ischemic stroke thrombolysis in patients taking dabigatran is controversial because of a presumed increased risk of symptomatic hemorrhagic transformation."3.80Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke. ( Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A, 2014)
" Therefore, we compared the incidence of bleeding and thrombo-embolic complications following cardiac rhythm device (CRD) implantations under dabigatran vs."3.80Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. ( Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P, 2014)
"Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF)."3.80Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H, 2014)
"Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous."3.80Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014)
"By using nationwide Danish prescription and patient registries, we identified 11,315 first-time dabigatran users with atrial fibrillation."3.80Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. ( Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F, 2014)
"We report a case of life-threatening haemoptysis after administration of dabigatran in a patient with bronchiectasis."3.80Massive haemoptysis following dabigatran administration in a patient with bronchiectasis. ( Hayama, M; Inoue, H; Mio, T; Wada, H, 2014)
"Epistaxis resulted in severe anemia in an 89-year-old Caucasian woman under a therapy with dabigatran for 12 months because of atrial fibrillation."3.80Dabigatran-induced lupus temporarily preventing blood group determination. ( Finsterer, J; Krutisch, G; Stöllberger, C; Wolf, HM, 2014)
"Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported."3.80Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014)
"The new oral anticoagulants (NOAC), dabigatran and rivaroxaban, have been demonstrated to be at least equivalent to warfarin for preventing cardiac thromboembolism (TE) in patients with atrial fibrillation (AF)."3.80Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. ( Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V, 2014)
"The clinical data and treatment summaries of 9 intracranial bleeds that developed during dabigatran treatment in 8 patients with non-valvular atrial fibrillation were retrospectively reviewed."3.80Intracranial hemorrhage during dabigatran treatment. ( Ago, T; Fujimoto, S; Kameda, K; Kitazono, T; Kokuba, K; Komori, M; Matsuoka, H; Nagata, S; Okada, Y; Shono, T; Yasaka, M; Yoshida, M, 2014)
"Dabigatran is an oral anticoagulant from the class of the direct thrombin inhibitors, indicated for prevention of thromboembolic events in patients with non valvular atrial fibrillation."3.80[Hemodialysis to remove anticoagulant dabigatran during emergencies]. ( Campbell, S; Carrizo, A, 2014)
"New oral anticoagulants (NOACs) offer an alternative to warfarin for preventing stroke in patients with atrial fibrillation."3.80Perioperative management of patients on new oral anticoagulants. ( Davidson, N; Galloway, SW; Lai, A; Thachil, J, 2014)
"To conduct an economic evaluation of the currently prescribed treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin, aspirin, and novel oral anticoagulants (NOACs) from a French payer perspective."3.80Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. ( Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T, 2014)
"Dabigatran, rivaroxaban, and apixaban have been approved for use in patients with atrial fibrillation based upon randomized trials demonstrating their comparable or superior efficacy and safety relative to warfarin."3.80Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. ( Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM, 2014)
" Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction."3.80Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. ( Barón, AE; Bradley, SM; Carey, EP; Cunningham, F; Grunwald, GK; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Pilote, L; Rumsfeld, JS; Schneider, PM; Shore, S; Turakhia, MP; Varosy, PD, 2014)
"In randomized trials, patients with atrial fibrillation (AF) receiving dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than those on warfarin."3.80Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. ( Alonso, A; Bengtson, LG; Chen, LY; Lakshminarayan, K; Lutsey, PL; MacLehose, RF, 2014)
"Dabigatran is one of the three newer oral anticoagulants (OACs) recently approved in the United States for stroke prevention in non-valvular atrial fibrillation (NVAF) patients."3.80Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. ( AbuDagga, A; Fu, AC; Kwong, WJ; Stephenson, JJ; Tan, H; Weintraub, WS, 2014)
"Dabigatran, an oral direct thrombin inhibitor, possesses several advantages over warfarin that can in principle simplify the management of stroke prevention in atrial fibrillation (AF)."3.80Continuation of dabigatran therapy in "real-world" practice in Hong Kong. ( Chan, EW; Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Leung, GK; Siu, CW; Tse, HF, 2014)
"This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥ 75), and the overall population (All) from a US Medicare payer perspective."3.80Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. ( Brand, S; Brueckmann, M; Clemens, A; Kansal, A; Lim, J; Noack, H; Peng, S; Sander, S; Sorensen, S, 2014)
"Clinical trial data suggest that dabigatran and warfarin have similar rates of major bleeding but higher rates of gastrointestinal bleeding."3.80Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. ( Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS, 2014)
" The purpose of this study was to estimate the change in medical costs related to stroke and major bleeding for each NOAC (apixaban, dabigatran, and rivoraxaban) relative to warfarin in a RW NVAF population."3.80Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. ( Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N, 2014)
"We applied enrollment criteria of 4 RCTs (RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) to 695 patients with AF taking warfarin, prospectively and consecutively collected at a university medical center; 500 patients with and 195 patients without stroke."3.80Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. ( Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH, 2014)
"The oral direct thrombin inhibitor dabigatran is increasingly used to prevent thromboembolic stroke in patients with atrial fibrillation (AF)."3.80On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. ( Antovic, JP; Beck, O; Eintrei, J; Hjemdahl, P; Malmström, RE; Muhrbeck, J; Pohanka, A; Rönquist-Nii, Y; Skeppholm, M, 2014)
" New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke."3.80[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014)
"This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin."3.80Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. ( Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014)
"Left atrial appendage occlusion devices are cost effective for stroke prophylaxis in atrial fibrillation when compared with dabigatran or warfarin."3.80Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation. ( Bennell, MC; Krahn, M; Micieli, A; Pham, B; Singh, SM; Wijeysundera, HC, 2014)
" Dabigatran has emerged as a promising alternative to vitamin K antagonists (VKAs) in non-valvular atrial fibrillation (NVAF)."3.80[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital]. ( Banfi, R; Fallani, F; Palazzi, N; Pugi, A, 2014)
"This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore."3.80Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. ( Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F, 2014)
"Our objectives were to investigate the cost effectiveness of apixaban, rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in patients with atrial fibrillation in a country with specialized anticoagulation clinics (the Netherlands) and in a country without these clinics (the UK)."3.80Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. ( de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI, 2014)
"Bleeding complications post-ablation were similar for warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation."3.80A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. ( Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R, 2014)
" A direct thrombin inhibitor, dabigatran etexilate (hereinafter referred to as dabigatran) was approved in the Russian Federation for prevention of thromboembolic complications in orthopaedic practice (2009), for prevention of ischaemic embologenic stroke in atrial fibrillation (2011) and for treatment of recurrent thrombosis of deep veins and pulmonary artery thromboembolism (2014)."3.80[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. ( Beliavskaia, OO; Vavilova, TV, 2014)
"We report a case of a patient receiving dabigatran who developed a life-threatening bleeding complication during cardiac ablation that rapidly resolved after administration of Factor Eight Inhibitor Bypassing Activity (FEIBA)."3.79Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. ( Dager, WE; Gosselin, RC; Roberts, AJ, 2013)
"To compare the management cost and cost-effectiveness of dabigatran with warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' perspectives."3.79Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital. ( Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM, 2013)
"This was a prospective observational study of ED patients under treatment with dabigatran or warfarin who were admitted with bleeding complications during a 6-month period."3.79Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. ( Berger, R; Chase, M; Ganetsky, M; Salhanick, SD, 2013)
" On admission, a computed tomography angiogram revealed acute bilateral PE, despite use of dabigatran for atrial fibrillation for approximately 5 years prior to admission."3.79Acute pulmonary emboli in a patient on long-term dabigatran therapy. ( Kujawski, SZ; Prom, R; Rafferty, JA, 2013)
"Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AF)."3.79Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. ( Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP, 2013)
"It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors."3.79[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013)
"To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin."3.79Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. ( Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE, 2013)
"Uninterrupted oral anticoagulant (OA) therapy with warfarin has become the standard of care at many centers performing catheter ablation of atrial fibrillation (AF)."3.79Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. ( Doppalapudi, H; Gunter, A; Kay, GN; Maddox, W; McElderry, HT; Osorio, J; Plumb, VJ; Yamada, T, 2013)
"Dabigatran is effective for both the prevention of stroke and bleeding in patients with atrial fibrillation (AF)."3.79Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. ( Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013)
"The use of dabigatran would lead to a significant reduction of strokes and deaths attributable to AF in France."3.79Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation. ( Chevalier, J; de Pouvourville, G; Giroud, M, 2013)
"A number of models exploring the cost-effectiveness of dabigatran versus warfarin for stroke prevention in atrial fibrillation have been published."3.79A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. ( Bradley-Kennedy, C; Kansal, AR; Monz, BU; Peng, S; Sorensen, SV, 2013)
"Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness."3.79Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013)
"In patients undergoing left atrial catheter ablation for AF or left atrial flutter, use of periprocedural dabigatran etexilate provides a safe and effective anticoagulation strategy compared to warfarin."3.79Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. ( Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP, 2013)
"Dabigatran was expected to replace warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (AF) who are warfarin naive, difficult to maintain in therapeutic range, or at risk of warfarin-related bleeding complications."3.79Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. ( Atay, JK; Barnes, GD; Coatney, J; Ehle, M; Fanikos, J; Froehlich, JB; Goldhaber, SZ; Piazza, G, 2013)
" We evaluated the influence of the putative etiological variables and the bleeding score, HAS-BLED score, on APTT values: age greater than 70 years, renal function, gender, dose of dabigatran, and the concomitant prescription of a P-glycoprotein inhibitor."3.79Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y, 2013)
"Percutaneous left atrial appendage (LAA) occlusion and novel pharmacological therapies are now available to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effectiveness of LAA occlusion compared with dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown."3.79Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. ( Micieli, A; Singh, SM; Wijeysundera, HC, 2013)
"Dabigatran is an oral direct thrombin inhibitor that is Food and Drug Administration-approved for prevention of stroke in patients with atrial fibrillation."3.79Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. ( Hallows, KR; Henry, BL; Maw, TT; Nolin, TD; Pastor-Soler, NM; Singh, T; Unruh, ML, 2013)
"Samples were obtained from 70 atrial fibrillation patients treated with dabigatran etexilate."3.79Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. ( Antovic, JP; Beck, O; Boija, EE; Eintrei, J; Hjemdahl, P; Malmström, RE; Norberg, EM; Onelöv, L; Pohanka, A; Rönquist-Nii, Y; Skeppholm, M; Söderblom, L, 2013)
"The results of a study to determine whether pharmacist monitoring in the crucial first months of dabigatran therapy in patients with atrial fibrillation or flutter can help optimize adherence and stroke-prevention outcomes are presented."3.79Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care. ( Han, SY; Lee, PY; Miyahara, RK, 2013)
"Between March 2011 and July 2012, dabigatran was prescribed to 404 Japanese patients with nonvalvular atrial fibrillation at The Cardiovascular Institute (Tokyo, Japan)."3.79"Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan. ( Aizawa, T; Kano, H; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Takai, H; Tanabe, H; Uejima, T; Yajima, J; Yamashita, T, 2013)
"Dabigatran is a direct thrombin inhibitor approved to help prevent thrombotic events in patients with atrial fibrillation."3.79Dental management considerations for a patient taking dabigatran etexilate: a case report. ( Henry, RG; Miller, CS; Romond, KK, 2013)
"The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear."3.79Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran, and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation (NVAF) patients."3.79Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. ( Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D, 2013)
"Cerebral microthromboembolism after atrial fibrillation (AF) ablation has been reported in 4-20% with perioperative warfarin."3.79The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. ( Hamasaki, S; Ichiki, H; Iriki, Y; Ishida, S; Maenosono, R; Miyata, M; Namino, F; Ninomiya, Y; Oketani, N; Okui, H; Tei, C, 2013)
"Warfarin is the primary treatment for those with atrial fibrillation at increased risk for stroke."3.79A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation. ( Azuma, S; Lum, CJ, 2013)
"Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding."3.79Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013)
"In an 89-year-old female with atrial fibrillation dabigatran had been started 11 days before admission, following a transitory ischemic attack."3.79Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy. ( Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C, 2013)
"Dabigatran is a direct thrombin inhibitor that reduces the risk of systemic embolism in patients with nonvalvular atrial fibrillation."3.79A case of dabigatran-associated acute renal failure. ( Julius, CJ; Negrete, H; Roy, P; Sarac, E; Shafi, ST, 2013)
" Six months before presentation, the patient was placed on Dabigatran etexilate (Dabigatran) (110 mg BID) for atrial fibrillation."3.79The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. ( Beydoun, A; Husari, A; Maakaron, JE; Sheik Ammar, A; Taher, A, 2013)
"Dabigatran is a recently introduced direct thrombin inhibitor licensed for use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation."3.79Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. ( Boga, T; Michel, J; Mundell, D; Sasse, A, 2013)
"It is not clear whether dabigatran is as safe and effective as uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF)."3.79Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. ( Bogun, F; Carrigan, T; Chugh, A; Crawford, T; Ghanbari, H; Good, E; Jongnarangsin, K; Kennedy, R; Kim, JS; Latchamsetty, R; Morady, F; Oral, H; Pelosi, F; Saint-Phard, W; She, F; Sinno, M; Suwanagool, A; Yokokawa, M, 2013)
"Dabigatran, administered orally as the prodrug dabigatran etexilate (DE), is a direct thrombin inhibitor shown to be effective in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF)."3.78Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. ( Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012)
"The concept of net clinical benefit has been used to quantify the balance between risk of ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral anticoagulant therapy (OAC) in the setting of non-valvular atrial fibrillation (AF), and has shown that patients at highest risk of stroke and thromboembolism gain the greatest benefit from OAC with warfarin."3.78Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. ( Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C, 2012)
"To present a case of dabigatran use for nonvalvular atrial fibrillation in a patient from a population for whom it has not been studied."3.78Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies. ( Fieland, D; Taylor, M, 2012)
"Dabigatran is a new oral anticoagulant recently approved for the prevention of stroke or systemic embolism in patients with atrial fibrillation (AF)."3.78Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. ( Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012)
"In patients undergoing AF ablation, periprocedural dabigatran use significantly increases the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy."3.78Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. ( Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR, 2012)
"The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed."3.78Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Easton, JD; Johnston, SC; Kamel, H; Kim, AS, 2012)
"For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel."3.78Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012)
"According to the update of the Finnish guidelines for management of patients with atrial fibrillation (AF) dronedarone should be used only in patients with non-permanent AF as a second line medication."3.78[Update on current care guidelines: atrial fibrillation]. ( , 2012)
"A 66-year-old woman treated with dabigatran for atrial fibrillation developed acute renal failure and upper gastrointestinal bleeding."3.78Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. ( Kouides, PA; Wychowski, MK, 2012)
" Based on various everyday situations in clinical routine, the purpose of the present expert recommendations is to provide appropriate perioperative and periinterventional management for patients with atrial fibrillation undergoing long-term treatment with the thrombin inhibitor dabigatran."3.78Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. ( Brodmann, M; Domanovits, H; Eber, B; Gottsauner-Wolf, M; Halbmayer, WM; Hiesmayr, JM; Kyrle, PA; Längle, F; Roithinger, FX; Watzke, H; Weltermann, A; Windhager, R; Wolf, C; Zweiker, R, 2012)
"Dabigatran etexelate is a new oral direct thrombin inhibitor that has been approved by the US Food and Drug Administration to prevent stroke in patients with nonvalvular atrial fibrillation."3.78Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. ( El Khoury, R; Lopez, G; Misra, V; Sangha, N, 2012)
"Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation."3.78Dabigatran for stroke prevention in atrial fibrillation. ( Diener, HC; Hohnloser, SH, 2012)
"Dabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal."3.78Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. ( Cheng, G; Tsui, KK; Wong, RS; You, JH, 2012)
"Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in patients with atrial fibrillation."3.78Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. ( Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S, 2012)
"We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years."3.78[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012)
"This case report describes agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a 70-year-old woman with paroxysmal atrial fibrillation (AF)."3.78Agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation. ( Hayashi, H; Horie, M; Kitoh, K; Mitsunami, K, 2012)
"In our cohort, bleeding-related complications 48 h and 1 week post-ablation were similar for warfarin and dabigatran."3.78A comparison of bleeding complications post-ablation between warfarin and dabigatran. ( Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K, 2012)
"Canadian patients with atrial fibrillation (AF) in whom anticoagulation is appropriate have two new choices for anticoagulation for prevention of stroke and systemic embolism--dabigatran etexilate (dabigatran) and rivaroxaban."3.78Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. ( Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV, 2012)
"Dabigatran has been rapidly adopted into ambulatory practice in the United States, primarily for treatment of atrial fibrillation, but increasingly for off-label indications."3.78National trends in oral anticoagulant use in the United States, 2007 to 2011. ( Alexander, GC; Kirley, K; Kornfield, R; Qato, DM; Stafford, RS, 2012)
"Assessment of the cost-effectiveness of dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain, from the perspective of the National Health System."3.78Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. ( Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC, 2012)
"Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin."3.78Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. ( Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM, 2012)
" She was on dabigatran for atrial fibrillation and aspirin, with intermittent intake of ibuprofen."3.78Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing "guidelines" in overdose and to find an "antidote"! ( Cirra, VR; Kamboj, J; Kamboj, R; Kottalgi, M; Shah, N, 2012)
"Warfarin, at a dose adjusted according to the INR, is the standard prophylactic anticoagulant for patients with atrial fibrillation and a major risk of thrombosis."3.78Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran. ( , 2012)
"We compared the efficacy and safety of warfarin, dabigartan, and clopidogrel used to prevent tromboembolism in 210 elderly patients with non-valvular atrial fibrillation depending on the age."3.78[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation]. ( Kanorsky, SG; Shevelev, VI, 2012)
"To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF."3.77Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011)
"Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent."3.77Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. ( Gage, BF; Shah, SV, 2011)
"Dabigatran etexilate is an oral direct thrombin inhibitor that is approved for use in thromboprophylaxis of atrial fibrillation and deep vein thrombosis."3.77Potential inaccuracy of point-of-care INR in dabigatran-treated patients. ( Baruch, L; Sherman, O, 2011)
"The central pharmacologic approach to stroke prevention in atrial fibrillation has recently changed with the approval of dabigatran by the US Food and Drug Administration (FDA)."3.77Dabigatran in atrial fibrillation: pharmacology and clinical trials. ( Ezekowitz, MD; Nagarakanti, R, 2011)
"To report an incident of a drug-induced exanthem during treatment with dabigatran in a patient without prior exposure to the drug."3.77Drug-induced exanthem following dabigatran. ( Blais, DM; Boyd, JM; Hummel, J; Whitehead, H, 2011)
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared."2.79Warfarin or dabigatran for treatment of atrial fibrillation. ( Ibrahim, S; Jespersen, J; Poller, L, 2014)
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms."2.79[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. ( Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014)
"Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit."2.78Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. ( Davidson, T; Husberg, M; Janzon, M; Levin, LÅ; Oldgren, J, 2013)
"Dabigatran is a direct thrombin inhibitor, does not require blood coagulation monitoring and limitation of vitamin K intake as well as very few drug interactions, and thus expected to be an oral anticoagulant alternative to warfarin."2.76[Expectation to and problems of thrombin inhibitor]. ( Uchiyama, S, 2011)
"Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor that has been developed as an alternative to vitamin K antagonists (VKAs)."2.50Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. ( Atallah, R; Bloom, BJ; Eisenberg, MJ; Filion, KB, 2014)
" In contrast to warfarin, most NOACs need dosage adjustments in renal impairment and are contraindicated in severe liver impairment, and there are no specific antidotes for treating NOAC-related over-anticoagulation."2.50New oral anticoagulants in practice: pharmacological and practical considerations. ( Bajorek, B; Wang, Y, 2014)
" However, in elderly patients with impaired renal function or considerable bleeding risks, label advice regarding dosing needs strict observation."2.50Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. ( Harder, S; Meyer Dos Santos, S, 2014)
"Warfarin and heparins have been the predominant anticoagulants used until the past decade."2.50The newer direct oral anticoagulants: a practical guide. ( Thachil, J, 2014)
" The dosage of warfarin requires regular adjustment dependent on the INR, to keep within a narrow therapeutic range of 2."2.50Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all? ( Foley, J; Kirchhof, P; Lip, GY, 2014)
"Dabigatran was the first NOAC approved and is a direct thrombin inhibitor."2.50Novel oral anticoagulants in non-valvular atrial fibrillation. ( da Silva, RM, 2014)
"Ischemic stroke is a severe complication of AF often resulting in disability or death."2.50[The use of dabigatran for prevention of ischemic stroke in patiets with atrial fibrillation: special features of treatment in different clinical situations]. ( Shchendrygina, AA, 2014)
" Much remains to be learned about the optimal use of the novel oral anticoagulants in CKD patients; additional studies about optimal dosing of the novel oral anticoagulants and frequency of monitoring renal function in CKD patients with atrial fibrillation are needed."2.49Stroke prevention in atrial fibrillation patients with chronic kidney disease. ( Brimble, KS; Eikelboom, JW; Hart, RG; Ingram, AJ; McMurtry, MS, 2013)
"Stroke is the most feared complication among patients with atrial fibrillation."2.49Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. ( Lopes, RD; Newby, LK; Truffa, AA, 2013)
"Dabigatran was the first of the agents to be widely available, and in the RE-LY study, dabigatran (150 mg dose) showed superiority to warfarin in preventing ischemic stroke and a significant reduction in intracranial bleeding."2.49New alternative anticoagulants in atrial fibrillation: the move beyond warfarin. ( Bhimani, AA; Hong, M, 2013)
"NOACs have shown a large reduction in intracranial hemorrhage compared with warfarin."2.49[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. ( Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L, 2013)
" Advantages and disadvantages to using these newer agents are presented, as are dosing adjustments for renal and hepatic impairment."2.49Outpatient management of oral anticoagulation in atrial fibrillation. ( Manning, JA, 2013)
"Stroke is a common disease, which is associated with high morbidity and high mortality."2.49[Anticoagulant therapy in stroke patients]. ( Grove, EL; Husted, SE; Kraglund, KL; Modrau, B, 2013)
"Warfarin has been the only available oral anticoagulant therapy for several decades."2.48Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome. ( Khemasuwan, D; Suramaethakul, N, 2012)
"Dabigatran is a direct thrombin (factor IIa) inhibitor that overcomes many of the limitations associated with warfarin."2.48Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation. ( Ibayashi, S; Matsumoto, M; Nagao, T; Nagata, K; Nakagawara, J; Tanahashi, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yasaka, M, 2012)
"Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate."2.48Dabigatran: a new chapter in anticoagulation. ( Ahmed, S; Levin, V; Malacoff, R; Martinez, MW, 2012)
"Dabigatran is an oral direct thrombin inhibitor."2.48[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation]. ( Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A, 2012)
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."2.48Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012)
"Cardioembolic cerebral ischemia can be prevented."2.48[Prevention of cardioembolic stroke]. ( Gil Núñez, A, 2012)
"Dabigatran is a direct thrombin inhibitor, which is not metabolized by cytochrome P450, and thus does not require blood coagulation monitoring or vitamin K intake limitation, or produce drug interaction."2.47[Dabigatran, a new oral anticoagulant]. ( Uchiyama, S, 2011)
" The vitamin K antagonist warfarin has traditionally been used in these patients but presents challenges in dosing and monitoring in these patients."2.47Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. ( Baker, WL; Bendel, SD; Bona, R, 2011)
"Dabigatran is an oral, reversible direct thrombin inhibitor approved in Europe and in several other countries for the prevention of venous thromboembolism after elective knee and hip replacement surgery."2.47Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents. ( Aizawa, Y; Atarashi, H; Inoue, H; Kamakura, S; Koretsune, Y; Kumagai, K; Mitamura, H; Ogawa, S; Okumura, K; Sugi, K; Yamashita, T; Yasaka, M, 2011)
"Dabigatran is a direct thrombin (FIIa) inhibitor, whereas Rivaroxaban and Apixaban are direct factor Xa (FXa) inhibitors."2.47[The new Anticoagulants - Relevant Facts for the GP]. ( Asmis, LM, 2011)
"Dabigatran is an oral direct thrombin inhibitor with a rapid onset."2.47Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. ( Augoustides, JG, 2011)
"Stroke is associated with the greatest mortality and morbidity in patients with atrial fibrillation (AF)."2.47A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. ( Banerjee, A; Lip, GY; Marín, F, 2011)
"Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity."2.47Pharmacological basis and clinical evidence of dabigatran therapy. ( Barez, A; Martínez, MP; Navarro-Dorado, J; Ramajo, M; Redondo, S; Tejerina, T, 2011)
"Dabigatran was administrated twice daily in a two dose regimens: 150 mg (5 patients) and 110 mg (14 patients)."1.42Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ( Dobrotová, M; Galajda, P; Ivanková, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2015)
"Compared to Vitamin K antagonists (VKA), novel oral anticoagulants (NOACs) appear to be safer in terms of major bleeding risks with added advantage of having fixed dosing schedules when used in patients with non-valvular atrial fibrillation (AF)."1.42Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants. ( Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J, 2015)
"Dabigatran was administered at a dose of 110-150 mg once or twice daily, depending on the renal function and age."1.42Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition. ( Fujino, T; Ikeda, T; Kabuki, T; Kiuchi, S; Kobayashi, K; Yamazaki, A; Yamazaki, J; Yamazaki, Y, 2015)
"Warfarin-related intracerebral hemorrhage carries a particularly high risk of neurologic deterioration and death because of a high rate of hematoma expansion of about 50%."1.40Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion. ( Damgaard, D; Simonsen, CZ; Steiner, T; Tietze, A, 2014)
" The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial."1.40A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. ( Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014)
" The objective of the study was to validate a dosing regimen for use of dabigatran in patients with mechanical heart valves."1.40Dabigatran use in mechanical heart valve patients. ( Pai, RG; Tafreshi, J; Zough, F, 2014)
"Direct-current cardioversion (DCCV) for persistent atrial fibrillation or atrial flutter (AF) carries a risk of thromboembolic events (TEs)."1.40Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. ( Groh, C; Passman, R; Yadlapati, A, 2014)
"Hypertension is the most frequent condition associated with atrial fibrillation (AF) and stroke, the most terrible complication of AF."1.39Can dabigatran improve blood pressure control? ( Barrios, V; Escobar, C, 2013)
" These drugs differ in a several important respects from warfarin; most notably they have a reliable dose-response effect which means they can be given without the need for monitoring."1.39New oral anticoagulants: their role and future. ( Laffan, M; Shapiro, S, 2013)
"Dabigatran is a new oral anticoagulant that does not require INR monitoring."1.39Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. ( Eichler, K; Plessow, R; Pletscher, M; Wieser, S, 2013)
"Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events."1.38The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012)
"Dabigatran is a direct thrombin inhibitor, acting like other members in its class (bivalirudin, argatroban) to impede the clotting process through selective and reversible binding with both free and clot-bound thrombin."1.38Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. ( Boniface, K; Moore, CH; Scott, J; Snashall, J, 2012)
"Dabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thrombin inhibitor."1.38Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. ( Garber, ST; Schmidt, RH; Sivakumar, W, 2012)
"Dabigatran was stopped and dalteparin 5000 International Units/bid and 40 μg alprostadil infusions were started."1.38Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy. ( Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C, 2012)

Research

Studies (543)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's542 (99.82)24.3611
2020's1 (0.18)2.80

Authors

AuthorsStudies
Aghoram, R1
Kumar, SM1
Rajasulochana, SR1
Kar, SS1
Aggarwal, R1
Alonso, A2
Lutsey, PL2
Chen, LY2
MacLehose, RF2
Bengtson, LGS1
Minhas, JS1
Mistri, AK1
Ummarino, D1
Sugiyama, T1
Lau, WCY1
Wong, ICK1
Chan, EW2
Calkins, H4
Nordaby, M1
Seligman, SJ1
Løfgren, B1
Pareek, M1
Larsen, JM1
Fender, AC1
Dobrev, D2
Holm, J1
Taskiran, M1
Schulman, S7
Berman, JP1
Halperin, JL10
Lenchus, JD1
Kasmeridis, C1
Lip, GY28
Apostolakis, S1
Fountzilas, C1
George, J1
Levine, R1
Dager, WE1
Gosselin, RC1
Roberts, AJ1
Chang, AM2
Ho, JC2
Yan, BP2
Yu, CM2
Lam, YY2
Lee, VW2
Hernández, M1
Suárez, C1
Masjuan, J2
Pazmiño, PA1
Kowey, PR4
Naccarelli, GV3
Berger, R1
Salhanick, SD1
Chase, M1
Ganetsky, M1
Rafferty, JA1
Prom, R1
Kujawski, SZ1
Bergh, M1
Marais, CA1
Miller-Jansön, H1
Salie, F1
Stander, MP1
Andreev, DA1
Gappoeva, ZK1
Sychev, DA1
Giliarov, MIu1
Harrington, AR1
Armstrong, EP1
Nolan, PE1
Malone, DC1
Bassiouny, M2
Saliba, W2
Rickard, J2
Shao, M2
Sey, A2
Diab, M2
Martin, DO2
Hussein, A2
Khoury, M2
Abi-Saleh, B2
Alam, S2
Sengupta, J2
Borek, PP2
Baranowski, B2
Niebauer, M2
Callahan, T2
Varma, N2
Chung, M2
Tchou, PJ2
Kanj, M2
Dresing, T2
Lindsay, BD2
Wazni, O2
Stiefelhagen, P2
Maddox, W1
Kay, GN3
Yamada, T1
Osorio, J1
Doppalapudi, H1
Plumb, VJ1
Gunter, A1
McElderry, HT1
Imamura, K1
Yoshida, A1
Takei, A1
Fukuzawa, K1
Kiuchi, K1
Takami, K1
Takami, M1
Itoh, M1
Fujiwara, R1
Suzuki, A1
Nakanishi, T1
Yamashita, S1
Matsumoto, A1
Hirata, K1
Ogbonna, KC1
Jeffery, SM1
Briongos Figuero, S1
García Santos-Gallego, C1
Badimón, JJ1
Chevalier, J1
Giroud, M1
de Pouvourville, G1
Sorensen, SV2
Peng, S3
Monz, BU3
Bradley-Kennedy, C2
Kansal, AR2
Pink, J2
Pirmohamed, M2
Hughes, DA2
Faria, R1
Spackman, E1
Burch, J1
Corbacho, B1
Todd, D1
Pepper, C1
Woolacott, N1
Palmer, S1
Harris, K1
Mant, J1
Hesselbjerg, LJ1
Pedersen, HS1
Asmussen, MB1
Petersen, KD1
Kaiser, DW1
Streur, MM1
Nagarakanti, R4
Whalen, SP1
Ellis, CR1
Yasaka, M4
Darius, H3
Sommer, S1
Atay, JK1
Fanikos, J2
Barnes, GD1
Ehle, M1
Coatney, J1
Piazza, G1
Froehlich, JB1
Goldhaber, SZ2
Pelargonio, G1
Perna, F1
Ahmad, Y2
Bergman, E1
Smith, JG1
Wieloch, M1
Braun, OÖ1
Svensson, P1
van der Pals, J1
Connolly, SJ19
Korhonen, M1
Noack, H5
Pooley, J1
Barrios, V3
Escobar, C3
Wassef, SN1
Abel, TJ1
Grossbach, A1
Viljoen, SV1
Jackson, AW1
Howard, MA1
Greenlee, JD1
Gallego, P1
Roldan, V2
Kawabata, M1
Yokoyama, Y1
Sasano, T1
Hachiya, H1
Tanaka, Y1
Yagishita, A1
Sugiyama, K1
Nakamura, T1
Suzuki, M1
Isobe, M1
Hirao, K1
Luis, SA1
Poon, K1
Luis, C1
Shukla, A1
Bett, N1
Hamilton-Craig, C1
Singh, SM2
Micieli, A2
Wijeysundera, HC2
Heidenreich, PA1
Desai, J1
Kolb, JM1
Weitz, JI5
Aisenberg, J2
Singh, T1
Maw, TT1
Henry, BL1
Pastor-Soler, NM1
Unruh, ML1
Hallows, KR1
Nolin, TD1
Bauer, KA1
Folyovich, A1
Varga, V1
Béres-Molnár, KA1
Vadasdi, K1
Bereczki, D1
Klein, HH1
Haines, DE1
Mead-Salley, M1
Salazar, M1
Marchlinski, FE2
Zado, E1
Yarmohammadi, H1
Nademanee, K1
Amnueypol, M1
Skanes, AC2
Saklani, P1
Eikelboom, JW17
Hart, RG6
Wallentin, L15
Reilly, P4
Oldgren, J9
Yang, S9
Yusuf, S18
Verheugt, FW1
Ezekowitz, MD19
Eikelboom, J9
Reilly, PA10
Brueckmann, M14
Pogue, J3
Alings, M3
Amerena, JV1
Avezum, A1
Baumgartner, I1
Budaj, AJ1
Chen, JH1
Dans, AL1
Di Pasquale, G2
Ferreira, J3
Flaker, GC1
Flather, MD1
Franzosi, MG2
Golitsyn, SP1
Halon, DA1
Heidbuchel, H1
Hohnloser, SH9
Huber, K2
Jansky, P1
Kamensky, G3
Keltai, M1
Kim, SS1
Lau, CP2
Le Heuzey, JY6
Lewis, BS1
Liu, L1
Nanas, J1
Omar, R2
Pais, P1
Pedersen, KE1
Piegas, LS1
Raev, D1
Smith, PJ1
Talajic, M1
Tan, RS1
Tanomsup, S1
Toivonen, L1
Vinereanu, D1
Xavier, D1
Zhu, J1
Wang, SQ1
Duffy, CO1
Themeles, E3
Antovic, JP2
Skeppholm, M2
Eintrei, J2
Boija, EE1
Söderblom, L1
Norberg, EM1
Onelöv, L1
Rönquist-Nii, Y2
Pohanka, A2
Beck, O2
Hjemdahl, P3
Malmström, RE2
Lee, PY1
Han, SY1
Miyahara, RK1
Gong, IY1
Kim, RB1
Brimble, KS1
McMurtry, MS2
Ingram, AJ1
Coyle, D1
Coyle, K1
Cameron, C1
Lee, K1
Kelly, S1
Steiner, S1
Wells, GA1
Boos, CJ1
Nam, M1
Camm, AJ1
Thachil, J3
Pike, G1
Keighley-Jones, L1
Nash, MJ1
Stöllberger, C8
Finsterer, J8
Diener, HC13
Truffa, AA1
Lopes, RD4
Newby, LK1
Jones, B1
Suzuki, S2
Sagara, K2
Otsuka, T2
Kano, H1
Matsuno, S2
Takai, H1
Uejima, T2
Oikawa, Y2
Koike, A2
Nagashima, K2
Kirigaya, H2
Yajima, J2
Tanabe, H1
Sawada, H2
Aizawa, T2
Yamashita, T4
Fraessdorf, M3
Romond, KK1
Miller, CS2
Henry, RG1
Shortt, B1
Robinson, M2
Bhimani, AA1
Hong, M1
Steinberg, BA4
Kim, S2
Piccini, JP4
Fonarow, GC2
Thomas, L2
Ansell, J3
Kowey, P1
Singer, DE3
Gersh, B2
Mahaffey, KW3
Hylek, E1
Go, AS3
Chang, P2
Peterson, ED2
Kamran, SH1
Muzammil, SM1
Kamal, AK1
Lowe, MP1
Collins, J1
Yehia, M1
Eaddy, N1
Deitelzweig, S2
Amin, A3
Jing, Y2
Makenbaeva, D3
Wiederkehr, D3
Lin, J2
Graham, J2
Assiri, A1
Al-Majzoub, O1
Kanaan, AO1
Donovan, JL1
Silva, M1
Bamimore, A1
Mounsey, JP1
Providência, R3
Albenque, JP3
Combes, S2
Bouzeman, A1
Casteigt, B1
Combes, N2
Narayanan, K1
Marijon, E5
Boveda, S3
Atar, S1
Wishniak, A1
Shturman, A1
Shtiwi, S1
Brezins, M1
Hasselblad, V1
Atwater, BD1
Bahnson, TD1
Washam, JB1
Alexander, JH2
Daubert, JP1
Noheria, A1
Asirvatham, SJ1
Aguilar, MI3
Kuo, RS1
Freeman, WD2
May, MA1
Gruel, Y1
Fauchier, L1
Szapary, L1
Fehér, G1
Bosnyák, E1
Deli, G1
Csécsei, P1
Lega, JC1
Bertoletti, L1
Durupt, S1
Epinat, M1
Mismetti, P1
Da Costa, A1
Laporte, S1
Dalen, JE1
Müller, P1
Topakian, R1
Sonnberger, M1
Nußbaumer, K1
Windpessl, M1
Eder, V1
Nesser, HJ1
Trenkler, J1
Haring, HP1
Zalesak, M1
Siu, K1
Francis, K1
Yu, C1
Alvrtsyan, H1
Rao, Y1
Walker, D1
Sander, S2
Miyasato, G1
Matchar, D1
Sanchez, H1
Wanat, MA1
Avorn, J4
Barry, M1
Ichiki, H1
Oketani, N1
Ishida, S1
Iriki, Y1
Okui, H1
Maenosono, R1
Namino, F1
Ninomiya, Y1
Miyata, M1
Hamasaki, S1
Tei, C1
Potpara, TS3
Easton, JD2
Hankey, GJ1
Van Gelder, IC1
Van Veldhuisen, DJ1
Hylek, EM4
Granger, CB3
Kappetein, AP1
Mack, MJ1
Blatchford, J1
Devenny, K1
Friedman, J3
Guiver, K1
Harper, R1
Khder, Y1
Lobmeyer, MT1
Maas, H1
Voigt, JU1
Simoons, ML1
Van de Werf, F3
Shurrab, M1
Morillo, CA1
Kansal, N1
Danon, A1
Newman, D1
Lashevsky, I1
Healey, JS4
Crystal, E1
Connolly, S4
Ezekowitz, M6
Roberts, A1
Lum, CJ1
Azuma, S1
Lane, S1
Artang, R1
Rome, E1
Nielsen, JD1
Vidaillet, HJ1
Sairaku, A2
Yoshida, Y2
Ando, M1
Hirayama, H2
Nakano, Y1
Kihara, Y1
Majeed, A2
Hwang, HG2
Ghanima, W1
Atar, D1
Sandset, PM1
Simonsen, CZ1
Steiner, T2
Tietze, A1
Damgaard, D1
Kornej, J1
Potpara, T1
Bin Abdulhak, AA2
Khan, AR2
Tleyjeh, IM1
Wimmer, AP3
Troncoso, A1
Diogène, E1
Rognoni, C1
Marchetti, M1
Quaglini, S1
Liberato, NL1
Cove, CL1
Hong, C1
Curnew, G1
Pullenayegum, E1
Holbrook, A1
Yap, LB1
Rusani, BI1
Umadevan, D1
Muhammad, Z1
Hussin, A1
Kaur, S1
Canestaro, WJ1
Patrick, AR2
Ito, K1
Matlin, OS2
Brennan, TA2
Shrank, WH2
Choudhry, NK3
Wood, P2
Krutisch, G2
Ribés-Cruz, JJ1
Torregrosa-Maicas, I1
Ramos-Tomás, C1
Solís-Salguero, MA1
Puchades-Montesa, MJ1
González-Rico, MA1
Juan-García, I1
Tomás-Simó, P1
Tejedor-Alonso, S1
Zambrano-Esteves, P1
Miguel-Carrasco, A1
Sidman, E1
Probst, LA1
Darko, W1
Miller, CD1
Manning, JA1
Holmes, DN1
Paul, G1
Bastovansky, A1
Kitazono, T2
Shapiro, S1
Laffan, M1
Hijazi, Z2
Andersson, U2
Siegbahn, A2
Clemens, A7
Kolias, TJ1
Zough, F1
Tafreshi, J1
Pai, RG1
Herrmann, R1
Thom, J1
Wood, A1
Phillips, M1
Muhammad, S1
Baker, R1
Larsen, TB7
Rasmussen, LH6
Gorst-Rasmussen, A4
Skjøth, F6
Rosenzweig, M3
Lane, DA8
Christensen, TD1
Bachellerie, B1
Ruiz, S1
Conil, JM1
Crognier, L1
Seguin, T1
Georges, B1
Fourcade, O1
Cheng, JW1
Barillari, G1
Kate, M1
Szkotak, A1
Witt, A1
Shuaib, A1
Butcher, K1
Weber, R3
Bloom, BJ1
Filion, KB2
Atallah, R1
Eisenberg, MJ2
Sharma, S1
Singh, S3
Stratta, P1
Battista, M1
Guglielmetti, G1
Gasparovic, H1
Petricevic, M1
Biocina, B1
Speirs, A1
Deakin, A1
Chin, PK2
Wright, DF2
Begg, EJ1
Wang, Y2
Bajorek, B1
Stewart, RA1
Hanon, O1
Liew, A3
Darvish-Kazem, S1
Douketis, JD2
Carley, B1
Griesbach, S1
Larson, T1
Krueger, K1
Kosiuk, J2
Koutalas, E2
Doering, M2
Sommer, P2
Rolf, S2
Breithardt, OA2
Nedios, S2
Dinov, B2
Hindricks, G2
Richter, S2
Bollmann, A2
Giglio, AF1
Basile, E1
Santangeli, P2
Di Biase, L2
Trotta, F1
Natale, A2
Gonzalez-Quesada, CJ1
Giugliano, RP2
Kongnakorn, T2
Phatak, H1
Kuznik, A1
Lanitis, T2
Liu, LZ1
Iloeje, U1
Hernandez, L1
Dorian, P2
Berthelot, E1
Lavenu-Bombled, C1
Orostegui-Giron, L1
Desconclois, C1
Assayag, P1
Sardar, P1
Nairooz, R1
Chatterjee, S1
Wetterslev, J1
Ghosh, J1
Aronow, WS1
Jourda, F1
Hireche, H1
Morais, J1
Capodanno, D1
Angiolillo, DJ1
Chan, NC1
Paikin, JS1
Hirsh, J1
Lauw, MN1
Ginsberg, JS1
Hayama, M1
Inoue, H2
Wada, H1
Mio, T1
Undas, A2
Pasierski, T1
Windyga, J1
Crowther, M2
Wolf, HM1
Huisman, MV3
Dubner, SJ1
Ma, CS1
Rothman, KJ1
Teutsch, C1
Zint, K2
Ackermann, D1
Bartels, DB1
Yadlapati, A1
Groh, C1
Passman, R1
Brunetti, L1
Chen, C1
White, J1
Antoniazzi, S1
Berdaï, D1
Conti, V1
Clementi, E1
Salvo, F1
Stepanyan, G1
Badhwar, N1
Lee, RJ1
Marcus, GM1
Lee, BK1
Tseng, ZH1
Vedantham, V1
Olgin, J1
Scheinman, M1
Gerstenfeld, EP2
Komori, M1
Kokuba, K1
Matsuoka, H1
Fujimoto, S1
Yoshida, M1
Kameda, K1
Shono, T1
Nagata, S1
Ago, T1
Okada, Y1
Salazar, CA1
del Aguila, D1
Cordova, EG1
Meyer Dos Santos, S1
Harder, S1
Inaishi, J1
Nogawa, S1
Mano, Y1
Yoshizaki, T1
Okada, S1
Wisløff, T1
Hagen, G1
Klemp, M1
Shafi, ST1
Negrete, H1
Roy, P1
Julius, CJ1
Sarac, E1
Carrizo, A1
Campbell, S1
Poller, L1
Jespersen, J1
Ibrahim, S1
Souto, JC1
Ruyra, X1
Bayes-Genis, A1
González-Juanatey, JR3
Lobos, JM2
Reverter, JC2
Becerra, V2
Soler-Martínez, S1
Martínez-Rubio, A3
González-Rojas, N2
Lai, A1
Davidson, N1
Galloway, SW1
Brannath, W1
Schmidt, S1
Brieger, D1
Hirano, T1
Cotté, FE1
Gaudin, AF1
Kachaner, I1
Durand-Zaleski, I1
Birnie, DH1
Essebag, V2
Alegret, JM1
Viñolas, X1
Arias, MA1
Rebollo, P1
Ràfols, C1
Martínez-Sande, JL1
Foley, J1
Kirchhof, P1
Desai, NR1
Krumme, AA1
Schneeweiss, S2
Brill, G1
Pezalla, EJ1
Spettell, CM1
Noll, G1
Noll, S1
Hürlimann, D1
Tkacheva, ON1
Akasheva, DU1
Fontaine, GV1
Mathews, KD1
Woller, SC1
Stevens, SM1
Lloyd, JF1
Evans, RS1
Spahr, J1
Ghosh, P1
Corelli, K1
Diogo, C1
Duarte, J1
Sobral, S1
Pestana, P1
Nzwalo, H1
Rita, H1
Sousa E Costa, J1
Zotova, IV1
Zateĭshchikov, DA1
Somani, R1
Mohajer, K1
Haley, C1
Simpson, CS2
Abdollah, H2
Baranchuk, A1
Redfearn, DP2
Michael, K1
Shore, S2
Carey, EP2
Turakhia, MP3
Jackevicius, CA1
Cunningham, F2
Pilote, L1
Bradley, SM1
Maddox, TM1
Grunwald, GK1
Barón, AE1
Rumsfeld, JS1
Varosy, PD1
Schneider, PM1
Marzec, LN1
Ho, PM2
Fernández de Velasco Pérez, D1
Konturek, P1
Hess, T1
Baker, WL2
Chamberlin, KW1
Tran, H1
Joseph, J1
Young, L1
McRae, S1
Curnow, J1
Nandurkar, H1
McLintock, C2
Bengtson, LG1
Lakshminarayan, K1
Aryal, MR2
Ukaigwe, A1
Pandit, A1
Karmacharya, P1
Pradhan, R1
Mainali, NR1
Pathak, R1
Jalota, L1
Bhandari, Y1
Donato, A1
Hana, A2
Berthold, C1
Gunness, VR1
Dooms, G1
Standhardt, H1
Koy, J1
Matgé, G1
Boecher-Schwarz, H1
Hertel, F1
Raatikainen, P1
Askonen, K1
Halinen, M1
Huikuri, H1
Koistinen, J1
Parikka, H1
Puurunen, M1
Virtanen, V1
AbuDagga, A1
Stephenson, JJ1
Fu, AC1
Kwong, WJ1
Tan, H1
Weintraub, WS1
Ho, MH2
Ho, CW2
Cheung, E2
Chan, PH3
Hai, JJ3
Chan, KH2
Leung, GK2
Tse, HF2
Siu, CW3
Orso, F1
Barucci, R1
Fracchia, S1
Mannarino, G1
Pratesi, A1
Fattirolli, F1
Turagam, MK1
Velagapudi, P1
Bongu, NR1
Kocheril, AG1
Samoš, M1
Stančiaková, L1
Ivanková, J1
Staško, J1
Kovář, F1
Dobrotová, M1
Galajda, P1
Kubisz, P1
Mokáň, M1
Brand, S1
Kansal, A1
Lim, J1
Sorensen, S1
Vaughan Sarrazin, MS2
Jones, M1
Mazur, A1
Chrischilles, E1
Cram, P1
Badal, M1
Mege, J1
Chaudhary, A1
Donato, AA1
Winkle, RA3
Mead, RH3
Engel, G3
Kong, MH3
Patrawala, RA3
Sarvananthan, S1
Punjabi, PP1
Stokes, M1
Wu, N1
Lawrence, JH1
Yoon, CH1
Park, YK1
Kim, SJ1
Lee, MJ1
Ryoo, S1
Kim, GM1
Chung, CS1
Lee, KH1
Kim, JS2
Bang, OY1
Seitz, J1
Beurtheret, S1
Muhrbeck, J1
Strack, A1
Konstantinides, S1
Rudakova, AV1
Tatarskiĭ, BA1
Senoo, K1
Czubek, U1
Góralczyk, T1
Zalewski, J1
Hifumi, T1
Takada, H1
Kiriu, N1
Bennell, MC1
Pham, B1
Krahn, M1
Pugi, A1
Fallani, F1
Palazzi, N1
Banfi, R1
Olesen, JB2
Sørensen, R1
Hansen, ML1
Lamberts, M1
Weeke, P1
Mikkelsen, AP1
Køber, L1
Gislason, GH1
Torp-Pedersen, C2
Fosbøl, EL1
Pollack, CV1
Levy, JH1
Sellke, FW1
Kamphuisen, P1
Bernstein, RA1
Darma, A1
Plitt, A1
Strasser, KM1
Qasem, A1
Madhusudhana, S1
Verma, A2
Cairns, JA2
Mitchell, LB1
Macle, L1
Stiell, IG1
Gladstone, D1
Cox, JL1
Ivers, N1
Leblanc, K1
Nattel, S1
Ammollo, CT1
Zaccaria, F1
Visino, F1
Testa, S3
Semeraro, N1
Colucci, M1
Messori, A2
Fadda, V2
Maratea, D2
Trippoli, S2
Marinai, C1
Kovács, T1
Shah, R1
Xie, F1
Kong, MC1
Lee, LH1
Ng, HJ1
Ko, Y1
Verhoef, TI1
Redekop, WK1
Hasrat, F1
de Boer, A1
Maitland-van der Zee, AH1
Kent, AP1
Ulrich, LR1
Mergenthal, K1
Petersen, JJ1
Roehl, I1
Rauck, S1
Kemperdick, B1
Schulz-Rothe, S1
Berghold, A1
Siebenhofer, A1
Graham, DJ1
Reichman, ME1
Wernecke, M1
Zhang, R1
Southworth, MR1
Levenson, M1
Sheu, TC1
Mott, K1
Goulding, MR1
Houstoun, M1
MaCurdy, TE1
Worrall, C1
Kelman, JA1
Redberg, RF1
Hernandez, I2
Baik, SH1
Piñera, A1
Zhang, Y2
Baber, U1
Mastoris, I1
Mehran, R1
Snipelisky, D2
Ray, JC1
Ung, R1
Duart, M1
Kauffman, C2
Kusumoto, F2
Douketis, J2
Bell, AD3
Yeung, CY1
Lau, KK1
Florkowski, CM1
Carney, EF1
Schilling, R1
Willems, S1
Owada, S1
Tomita, H1
Kinjo, T1
Ishida, Y1
Itoh, T1
Sasaki, K1
Horiuchi, D1
Kimura, M1
Sasaki, S1
Okumura, K2
da Silva, RM1
Beliavskaia, OO1
Vavilova, TV1
Hajhosseiny, R1
Sabir, I1
Armbruster, HL1
Lindsley, JP1
Moranville, MP1
Habibi, M1
Khurram, IM1
Spragg, DD1
Berger, RD1
Marine, JE1
Pontillo, D1
Patruno, N1
Gorzelak-Pabiś, P1
Duraj, I1
Szlagowska, L1
Ciastkowska, A1
Broncel, M1
Moustafa, F1
Milhaud, G1
Dublanchet, N1
Lebreton, A1
Dutheil, F1
Schmidt, J1
Forslund, T1
von Euler, M1
Johnsson, H1
Holmström, M1
Wettermark, B1
Arepally, GM1
Ortel, TL1
Chan, KE1
Edelman, ER1
Wenger, JB1
Thadhani, RI1
Maddux, FW1
Rockey, DC1
Einecke, D1
Hasler, S1
Feng, X1
Huan, Y1
Lv, Y1
Garg, P1
Ripley, DP1
Shchendrygina, AA1
Brais, C1
Larochelle, J1
Turgeon, M1
Tousignant, A1
Blais, L1
Perreault, S1
Farand, P1
Letemplier, G1
Beauchesne, M1
Patel, AD1
Tan, MK1
Angaran, P1
Berall, M1
Bucci, C1
Demchuk, AM1
Goldin, L1
Green, MS1
Gregoire, JC1
Gross, PL1
Heilbron, B1
Lin, PJ1
Ramanathan, K1
Skanes, A1
Wheeler, BH1
Goodman, SG1
Krishnamoorthy, A1
Sherwood, MW1
Becker, RC1
Yeh, CH1
Hogg, K1
Scheppach, W1
Meesmann, M1
Bosch, J1
Lambert-Kerzner, A1
Glorioso, TJ1
Longo, L1
Jackevicius, C1
Rose, A2
Kmietowicz, Z1
Wood, K1
Abraham, NS1
Alexander, GC3
Heien, H1
Haas, LR1
Crown, W1
Shah, ND1
Chang, HY1
Zhou, M1
Tang, W1
Okubo, K1
Kuwahara, T1
Takagi, K1
Takigawa, M1
Nakajima, J1
Watari, Y1
Nakashima, E1
Yamao, K1
Fujino, T2
Tsutsui, H1
Takahashi, A1
Park, CI1
Pruvot, E1
Jadidi, A1
Lehrmann, H1
Arentz, T1
Zimmermann, M1
Phillips, R1
Nagao, T2
Inden, Y2
Shimano, M1
Fujita, M1
Yanagisawa, S1
Kato, H1
Ishikawa, S1
Miyoshi, A1
Okumura, S1
Ohguchi, S1
Yamamoto, T1
Yoshida, N1
Hirai, M1
Murohara, T2
Hilpert, U1
Ameri, AA1
Lythgoe, M1
Yamazaki, Y1
Yamazaki, A1
Kabuki, T1
Kiuchi, S1
Kobayashi, K1
Yamazaki, J1
Ikeda, T1
Lewis, LS1
Miyares, MA1
Horjus, DL1
van Montfrans, GA1
Brewster, LM1
Klil-Drori, A1
Azoulay, L1
Kreuzer, J1
Liu, S1
Kim, CO1
Lucyk, SN1
Henriksen, DP1
Hansen, MR1
Damkier, P1
Zeus, T1
Kelm, M1
Bode, C3
Koretz, RL1
Lavine, JB1
Schaefer, JK1
McBane, RD1
Wysokinski, WE1
Torjesen, I1
Jimenez, D1
Jamil-Copley, S1
Kanagaratnam, P1
Broukhim, M1
Gil Núñez, A2
Freeman, JV1
Zhu, RP1
Owens, DK1
Garber, AM1
Hutton, DW1
Wang, PJ1
Messinger-Rapport, B1
Miranda, RI1
Michael, KA1
Baranchuk, AM1
Chernick, M1
Aikens, TH2
Flaker, G2
Brugada, J1
Parekh, A1
Ahrens, I1
Peter, K1
Giorgi, MA1
Cohen Arazi, H1
Gonzalez, CD1
Di Girolamo, G1
Wann, LS5
Curtis, AB5
Ellenbogen, KA5
Estes, NA3
Jackman, WM3
January, CT3
Lowe, JE5
Page, RL3
Slotwiner, DJ3
Stevenson, WG5
Tracy, CM3
Fuster, V3
Rydén, LE2
Cannom, DS2
Crijns, HJ4
Olsson, SB2
Prystowsky, EN2
Tamargo, JL2
Jacobs, AK2
Anderson, JL2
Albert, N2
Creager, MA2
Ettinger, SM2
Guyton, RA2
Hochman, JS2
Kushner, FG2
Ohman, EM2
Yancy, CW2
Calvo Romero, JM1
Samama, CM1
Kirsch, B1
Hori, M1
Uchiyama, S3
Gums, JG1
Beasley, BN1
Unger, EF1
Temple, R1
Edwards, DB1
Silverberg, J1
Berg, AM1
Cannon, CP2
Stecker, EC1
Bendel, SD1
Bona, R1
Kaatz, S1
Varrone, J1
Kooiman, J1
van de Peppel, WR1
van der Meer, FJ1
Rutzen-Lopez, H1
Khanna, V1
Vkhanna, V1
Reynolds, MR1
Reynolds, M1
Shah, SV1
Gage, BF1
Dumont, B1
Faille, D1
Ajzenberg, N1
Sawaya, FJ1
Musallam, KM1
Arnaout, S1
Rabah, A1
Sawaya, J1
Rahme, RJ1
Bernstein, R1
Batjer, HH1
Bendok, BR1
Ogawa, S1
Koretsune, Y1
Aizawa, Y1
Atarashi, H1
Kamakura, S1
Kumagai, K2
Mitamura, H1
Sugi, K1
Viles-Gonzalez, JF1
Lee, TH1
Baruch, L1
Sherman, O1
Shapiro, T1
Gage, L1
Shin, DI1
Eckardt, L1
del Zoppo, GJ1
Eliasziw, M1
Asmis, LM1
Ganjehei, L1
Massumi, A1
Razavi, M1
Rasekh, A1
Eerenberg, ES1
van Es, J1
Sijpkens, MK1
Büller, HR1
Kamphuisen, PW1
Mega, JL1
Averkov, OV1
Whitehead, H1
Boyd, JM1
Blais, DM1
Hummel, J1
Riva, L1
Pernod, G1
Hunchuck, JE1
Lake, JD1
Pengo, V2
Crippa, L2
Falanga, A2
Finazzi, G2
Marongiu, F2
Palareti, G3
Poli, D2
Tiraferri, E2
Tosetto, A2
Tripodi, A3
Manotti, C2
Lehr, T2
Haertter, S2
Liesenfeld, KH1
Staab, A1
Weimar, C1
Kaeufer, T1
Henry, DM1
Augoustides, JG1
Acharjee, S1
Banerjee, A2
Marín, F2
Yates, SW1
Beyth, RJ1
Landefeld, CS1
Al-Khatib, SM1
Patel, MR1
Panchenko, EP1
Garwood, CL1
Hwang, JM1
Moser, LR1
Moser, M1
Casado Naranjo, I1
Portilla-Cuenca, JC1
Jiménez Caballero, PE1
Calle Escobar, ML1
Romero Sevilla, RM1
Redondo, S1
Martínez, MP1
Ramajo, M1
Navarro-Dorado, J1
Barez, A1
Tejerina, T1
Moore, CH1
Snashall, J1
Boniface, K1
Scott, J1
Fieland, D1
Taylor, M1
Stangier, J1
van Ryn, J1
Golwala, H1
Dib, C1
Tafur, A1
Abu-Fadel, MS1
Parry, PV1
Engh, JA1
Hacke, W1
Govindarajan, R1
Salgado, E1
Reynolds, S1
Parra, D1
Rosenstein, RS1
Reiffel, JA1
Morales-Vidal, S1
Schneck, MJ1
Flaster, M1
Biller, J1
Funada, R1
Tendera, M1
Syzdół, M1
Parma, Z1
Knight, BP1
Lakkireddy, D1
Reddy, YM1
Vanga, SR1
Swarup, V1
Pimentel, R1
Mansour, MC1
D'Avila, A1
Sanchez, JE1
Burkhardt, JD1
Chalhoub, F1
Mohanty, P1
Coffey, J1
Shaik, N1
Monir, G1
Reddy, VY1
Ruskin, J1
Kamel, H1
Johnston, SC1
Kim, AS1
You, JJ1
Howard, PA1
Eckman, MH1
Fang, MC1
Hughes, M1
Spencer, FA1
Manning, WJ1
Lip, GYH1
Goto, S1
Soff, GA1
Quinlan, DJ2
Adcock, AK1
Lee-Iannotti, JK1
Hoffman-Snyder, CR1
Wingerchuk, DM1
Wellik, KE1
Demaerschalk, BM1
Ali, A1
Bailey, C1
Abdelhafiz, AH1
Khemasuwan, D1
Suramaethakul, N1
Garber, ST1
Sivakumar, W1
Schmidt, RH1
Okada, M1
Okada, K1
DiNicolantonio, JJ1
Ibayashi, S1
Matsumoto, M1
Nagata, K1
Nakagawara, J1
Tanahashi, N1
Tanaka, K1
Toyoda, K1
Katsnelson, M1
Sacco, RL1
Moscucci, M1
Ahmed, S1
Levin, V2
Malacoff, R1
Martinez, MW2
Wychowski, MK1
Kouides, PA1
Reiter, M1
Schäffl-Doweik, L1
Baker, RI1
Harper, P1
Moey, AW1
Koblar, SA1
Chryssidis, S1
Jannes, J1
Sternotte, A1
Douxfils, J1
Chatelain, B1
Chatelain, C1
Mullier, F1
Dogné, JM1
Spinewine, A1
Duh, PD1
Leuckx, PS1
Warnez, PM1
Grandi, SM1
Shimony, A1
Weltermann, A1
Brodmann, M1
Domanovits, H1
Eber, B1
Gottsauner-Wolf, M1
Halbmayer, WM1
Hiesmayr, JM1
Kyrle, PA1
Längle, F1
Roithinger, FX1
Watzke, H1
Windhager, R1
Wolf, C1
Zweiker, R1
Lee, VH1
Conners, JJ2
Prabhakaran, S2
Varughese, CJ1
Kuo, R1
Lewalter, T1
Shaheen, MH1
Das, P1
Koshy, SK1
Jha, SK1
Kabra, R1
Sangha, N1
El Khoury, R1
Misra, V1
Lopez, G1
Polovina, MM1
Licina, MM1
Stojanovic, RM1
Prostran, MS1
Davidson, T1
Husberg, M1
Janzon, M1
Levin, LÅ1
Rakusan, S1
Wimpissinger, FT1
Mantha, S1
You, JH1
Tsui, KK1
Wong, RS1
Cheng, G1
LaHaye, SA1
Gibbens, SL1
Ball, DG1
Day, AG1
Testa, L1
Agnifili, M1
Latini, RA1
Mattioli, R1
Lanotte, S1
De Marco, F1
Oreglia, J1
Latib, A1
Pizzocri, S1
Laudisa, ML1
Brambilla, N1
Bedogni, F1
Lillo-Le Louët, A1
Wolf, M1
Soufir, L1
Galbois, A1
Dumenil, AS1
Offenstadt, G1
Samama, MM1
Kaseno, K1
Naito, S1
Nakamura, K2
Sakamoto, T1
Sasaki, T1
Tsukada, N1
Hayano, M1
Nishiuchi, S1
Fuke, E1
Miki, Y1
Yamashita, E1
Oshima, S1
Tada, H1
Gagne, JJ1
Reinke, T1
Kalodiki, E1
Lewis, B1
Fareed, J1
Harenberg, J2
Marx, S2
Marder, VJ1
Wehling, M2
Weiss, C1
Reed, SD1
Moia, M1
Siragusa, S1
Huang, C1
Siu, M1
Vu, L1
Wong, S1
Shin, J1
Shevelev, VI2
Kanorskiĭ, SG1
Husari, A1
Beydoun, A1
Sheik Ammar, A1
Maakaron, JE1
Taher, A1
Zhang, S1
Destephan, C1
Waller, AH1
Patel, RJ1
Dhruvakumar, S1
Mazza, V1
Gerula, C1
Maher, J1
Kaluski, E1
Hayashi, H1
Kitoh, K1
Mitsunami, K1
Horie, M1
Testai, FD1
Prussak, K1
Johns, G1
Venkatachalam, K1
Taylor, J3
Kosar, L1
Jin, M1
Kamrul, R1
Schuster, B1
Sharma, M1
Roskell, N1
Lee, V1
Pisters, R2
Ten Cate, H1
Alonso-Coello, P1
Zhou, Q1
Guyatt, G1
Seiffge, D1
Nedeltchev, K1
Lyrer, P1
Kirley, K1
Qato, DM1
Kornfield, R1
Stafford, RS1
Álvarez-Sabin, J1
Oyagüez, I1
Rochwerg, B1
Xenodemetropoulos, T1
Spyropoulos, A1
Yokoi, K1
Isoda, K1
Kimura, T1
Adachi, T1
Turpie, AG1
Kreutz, R1
Llau, J1
Norrving, B1
Haas, S1
Konduru, SV1
Cheema, AA1
Jones, P1
Li, Y1
Ramza, B1
Esmon, CT1
Moubarak, G1
Badenco, N1
Dreyfus, J1
Simion, C1
Delos Paquet, A1
Cazeau, S1
Cador, R1
Gonzalez, MD1
Michel, J1
Mundell, D1
Boga, T1
Sasse, A1
Koziński, M1
Obońska, K1
Kubica, A1
Navarese, EP1
Kubica, J1
Aalbers, J3
Hardy, G1
Durin, O1
Donato, G1
Nanetti, M1
Foffa, A1
Inama, G1
Furman, NV1
Kuvshinova, LE1
Dovgalevskiĭ, IaP1
Bytzer, P1
Formella, S1
Blanco-Molina, A1
Nin, T1
Kamiya, H1
Tatematsu, Y1
Nanasato, M1
Kamboj, J1
Kottalgi, M1
Cirra, VR1
Shah, N1
Kamboj, R1
Dabitz, R1
Ochs, G1
Nieuwlaat, R1
Boehlen, F1
de Moerloose, P1
Shamoun, FE1
Martin, EN1
Money, SR1
She, F1
Jongnarangsin, K1
Chugh, A1
Latchamsetty, R1
Ghanbari, H1
Crawford, T1
Suwanagool, A1
Sinno, M1
Carrigan, T1
Kennedy, R1
Saint-Phard, W1
Yokokawa, M1
Good, E1
Bogun, F1
Pelosi, F1
Morady, F1
Oral, H1
Coccheri, S1
Orlando, D1
Kanorsky, SG1
Deitelzweig, SB1
Pletscher, M1
Plessow, R1
Eichler, K1
Wieser, S1
Brill, D1
Greenspon, AJ1
Kraglund, KL1
Husted, SE1
Modrau, B1
Grove, EL1
de Gea-García, JH1
Alvarez, M1
Ruiz-Villa, G1
Jiménez-Parra, JD1
Brem, E1
Koyfman, A1
Foran, M1
Contractor, T1
Kis, Z1
Földesi, C1
Pál, M1
Som, Z1
Csillik, A1
Abrahám, P1
Temesvári, A1
Fontos, G1
Szatmári, A1
Andréka, P1
Kardos, A1

Clinical Trials (37)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288]1,200 participants (Anticipated)Interventional2020-12-16Active, not recruiting
Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.[NCT04462003]Phase 3100 participants (Anticipated)Interventional2019-07-03Recruiting
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600]Phase 318,113 participants (Actual)Interventional2005-12-31Completed
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes[NCT00808067]Phase 35,897 participants (Actual)Interventional2008-11-30Completed
An Epidemiological Study to Evaluate the Use of Vitamin K Antagonists and New Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients in Turkey[NCT02354456]4,100 participants (Anticipated)Observational [Patient Registry]2015-01-31Recruiting
Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386]Phase 360 participants (Actual)Interventional2017-05-03Completed
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)[NCT03515083]100 participants (Actual)Interventional2017-07-17Completed
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710]10,179 participants (Actual)Observational2010-06-30Completed
This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mech[NCT02128841]Phase 212 participants (Actual)Interventional2012-09-30Terminated (stopped due to not enough patients)
A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban[NCT04142658]Phase 3863 participants (Actual)Interventional2020-05-01Terminated (stopped due to Safety)
Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients[NCT02211326]660 participants (Actual)Interventional2014-09-01Completed
Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve[NCT01505881]Phase 2158 participants (Actual)Interventional2011-12-31Terminated
A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt[NCT01452347]Phase 2328 participants (Actual)Interventional2011-10-31Terminated
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.[NCT00558259]Phase 31,353 participants (Actual)Interventional2007-11-30Completed
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatm[NCT00680186]Phase 32,589 participants (Actual)Interventional2008-04-30Completed
A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembo[NCT00329238]Phase 32,867 participants (Actual)Interventional2006-05-31Completed
A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following In[NCT00291330]Phase 32,564 participants (Actual)Interventional2006-02-28Completed
GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase I)[NCT01428765]1,096 participants (Actual)Observational2011-05-31Completed
GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)[NCT01671007]10,471 participants (Actual)Observational2012-08-22Completed
GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)[NCT01468701]37,235 participants (Actual)Observational2011-11-07Completed
Effectivity of a Joint Didactic Intervention by School for Patients on Inappropriate Control Prothrombin Time Anticoagulated Patients. Protocol for Developing a Randomized and Controlled Clinical Trial[NCT03647254]1 participants (Anticipated)Interventional2018-09-01Recruiting
A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035]1,496 participants (Actual)Observational2015-03-22Completed
Pilot Intervention to Improve Adherence to Dabigatran for Patients With Atrial Fibillation[NCT01578044]12 participants (Actual)Interventional2012-01-31Completed
Italian Registry In the Setting of AF Ablation With Rivaroxaban[NCT04315974]250 participants (Anticipated)Observational [Patient Registry]2020-05-15Recruiting
Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709]Phase 47 participants (Actual)Interventional2016-04-30Completed
The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236]150 participants (Actual)Interventional2016-07-31Completed
RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407]Phase 4154 participants (Actual)Interventional2016-12-31Completed
SPRINT-AF: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation[NCT01733160]2,499 participants (Actual)Observational2013-11-30Completed
Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777]4,162 participants (Actual)Observational2014-04-30Completed
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928]Phase 3200 participants (Actual)Interventional2017-06-14Active, not recruiting
Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838]1,200 participants (Anticipated)Observational2023-08-09Recruiting
Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation[NCT02623049]150 participants (Anticipated)Observational2015-11-30Recruiting
Correlation Between Bleeding Complication and Treatment Failure of DOAC and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04597593]200 participants (Actual)Observational2020-10-07Completed
Investigation of Genetic Variations on Patients With Adverse Events While on Direct Oral Anticoagulants (DOACs)[NCT04580589]210 participants (Actual)Observational2021-02-01Completed
Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445]Phase 4160 participants (Actual)Interventional2019-05-01Completed
Investigation of Genetic Variations on Patients With Adverse Drug Events While on Direct Oral Anticoagulants (DOACs)[NCT04247919]3 participants (Actual)Observational2020-01-10Terminated (stopped due to Limitations to recruitment due to COVID-19)
Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management[NCT03182218]1,100 participants (Actual)Observational2015-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Abnormal Liver Function Test

Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months

Interventionparticipants (Number)
Dabigatran 110 mg11
Dabigatran 150 mg14
Warfarin21

Yearly Event Rate for Composite Endpoint of Stroke/SEE

Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg1.54
Dabigatran 150 mg1.11
Warfarin1.71

Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death

Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.85
Dabigatran 150 mg4.32
Warfarin5.20

Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death

Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.26
Dabigatran 150 mg3.68
Warfarin4.35

Bleeding Events (Major and Minor)

"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage) (Number)
Major bleedsMinor bleeds
Dabigatran 110 mg2.9913.16
Dabigatran 150 mg3.5514.85
Warfarin3.8116.37

Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)

Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage)] (Number)
intracerebral hemorrhageintracranial hemorrhage (ICH)
Dabigatran 110 mg0.120.23
Dabigatran 150 mg0.100.32
Warfarin0.380.76

Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~a. In subjects not undergoing PCI or CABG a subject should have fulfilled at least 2 of the following: i. Typical prolonged severe chest pain or related symptoms or signs suggestive of MI. ii. Elevation of troponin or CK-MB to more than upper level of normal (ULN) or, if CK-MB was elevated at baseline, re-elevation to more than 50% increase above the previous level. iii. Development of significant Q-waves in at least 2 adjacent ECG leads. b. After percutaneous coronary intervention (within 24h). c. After coronary artery bypass grafting (within 72h). d. Silent myocardial infarction. e. Myocardial infarction could also have been demonstrated at autopsy." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.72
Dabigatran 150 mg0.66

Annualized Rate of Subjects With Any Bleeds (Major Plus Minor)

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg9.44
Dabigatran 150 mg11.20

Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE)

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg1.60
Dabigatran 150 mg1.47

Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg4.40
Dabigatran 150 mg4.02

Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction (MI), All Cause Death and Major Bleed

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg6.65
Dabigatran 150 mg7.14

Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg3.51
Dabigatran 150 mg3.32

Annualized Rate of Subjects With Intra-Cranial Hemorrhage (ICH)

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25. (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.28
Dabigatran 150 mg0.33

Annualized Rate of Subjects With Minor Bleeds

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. Minor bleeds were classified as associated with study medication discontinuation (temporary or permanent) or not." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg7.49
Dabigatran 150 mg8.98

Death, Annualized Rate of Subject Death

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Deaths were classified as being vascular (sudden/arrhythmic, pump failure death, or other vascular, including bleeding) or non-vascular, due to other specified causes (e.g., malignancy), or of unknown etiology." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg3.18
Dabigatran 150 mg2.99

Deep Vein Thrombosis, Annualized Rate of Subjects With DVT

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Deep Vein Thrombosis (DVT) was generally documented by one of the following:~abnormal compression ultrasound (CUS),~an intraluminal filling defect on venography." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.06
Dabigatran 150 mg0.11

Major Bleeding, Annualized Rate of Subjects With Major Bleeds

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Major bleeding must have satisfied one or more of the following criteria:~Bleeding associated with a reduction in hemoglobin of at least 20 g/L~Required transfusion of at least 2 units of blood or packed cells~Symptomatic bleeding in a critical area or organ: intraocular, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intra-articular, pericardial, gastrointestinal~Major bleed were classified as life-threatening if they met one or more of the following criteria:~Reduction in hemoglobin of at least 50 g/L~Transfusion of at least 4 units of blood or packed cells~Symptomatic intracranial bleeding, either subdural or intracerebral~Associated with hypotension requiring use of intravenous inotropic agents~Required surgical intervention to stop bleeding~Resulted in death" (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg2.79
Dabigatran 150 mg3.59

Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Systemic embolism was an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts), and was to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.25
Dabigatran 150 mg0.23

Pulmonary Embolism (PE), Annualized Rate of Subjects With PE

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Pulmonary Embolism was generally documented by one of the following:~an intraluminal filling defect in segmental or more proximal branches on spiral CT scan~an intraluminal filling defect or an extension of an existing defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram~a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)~inconclusive spiral CT, pulmonary angiography or lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasound or venography." (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg0.10
Dabigatran 150 mg0.12

Stroke, Annualized Rate of Subjects With Stroke

"Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.~Stroke was an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke was categorized as ischemic or hemorrhagic or cause unknown based on computerized tomography (CT), magnetic resonance (MR) scanning or autopsy. Fatal stroke was defined as death from any cause within 30 days of stroke. Severity of stroke was assessed by modified Rankin score at discharge from hospital" (NCT00808067)
Timeframe: up to 43 months

Interventionpercentage of subject-years (Number)
Dabigatran 110 mg1.39
Dabigatran 150 mg1.26

Percentage of Patients With AEs Leading to Discontinuation of Trial Drug

"Percentage of patients with Adverse Events leading to discontinuation of trial drug.~Prespecified clinical outcome events were not recorded as Adverse Events." (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

Interventionpercentage of participants (Number)
Dabigatran Etexilate (DE)5.1
Warfarin1.7

Percentage of Patients With Any Adverse Event (AE)

Percentage of patients with Adverse Events. Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

Interventionpercentage of participants (Number)
Dabigatran Etexilate (DE)39.4
Warfarin37.3

Percentage of Patients With Serious AEs

Percentage of patients with Serious Adverse Events (SAE). Prespecified clinical outcome events were not recorded as Adverse Events. (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

Interventionpercentage of participants (Number)
Dabigatran Etexilate (DE)3.0
Warfarin6.8

Percentage of Deaths, Venous Thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attacks (TIA), Strokes, Systemic Embolism, and Valve Thrombosis.

"Clinical efficacy outcome events presented are:~Death, Venous thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attack (TIA), Stroke, Systemic embolism and Valve thrombosis" (NCT01505881)
Timeframe: From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)

,
Interventionpercentage of participants (Number)
DeathVenous thromboembolismMyocardial InfarctionTransient Ischaemic AttackStrokeSystemic embolismValve thrombosis
Dabigatran Etexilate (DE)0.00.01.01.03.00.02.0
Warfarin1.70.00.00.00.00.00.0

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~(As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients)~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 12

Interventionng/mL (Geometric Mean)
Observed108.21
Predicted104.80

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 2

Interventionng/mL (Geometric Mean)
Observed84.08
Predicted99.55

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 4

Interventionng/mL (Geometric Mean)
Observed104.43
Predicted109.36

Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1

"Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) .~Despite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population." (NCT01452347)
Timeframe: Week 1

Interventionng/mL (Geometric Mean)
Observed73.86
Predicted99.52

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12

Percentage of patients with observed Ctrough,ss value < 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Patients Evaluated7.4

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1

Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 1

Interventionpercentage of participants (Number)
Patients Evaluated26.9

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2

Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 2

Interventionpercentage of participants (Number)
Patients Evaluated19.2

Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4

Percentage of patients with observed Ctrough,ss value < 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group. (NCT01452347)
Timeframe: Week 4

Interventionpercentage of participants (Number)
Patients Evaluated9.8

Centrally Confirmed Cardiovascular Events During the Treatment Period

Cardiovascular events that occurred during the treatment period + 3 days were summarised by treatment groups. (NCT00558259)
Timeframe: 6 months

Interventionparticipants (Number)
Dabigatran3
Placebo2

Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period

Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months

InterventionParticipants (Number)
Dabigatran1
Placebo14

Centrally Confirmed Symptomatic Recurrent Deep Venous Thrombotic (DVT) Events During the Intended Treatment Period

Number of the participants with centrally confirmed symptomatic recurrent deep venous thrombotic (DVT) events during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months

InterventionParticipants (Number)
Dabigatran2
Placebo23

Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Excluding Unexplained Death During the Intended Treatment Period

Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months

InterventionParticipants (Number)
Dabigatran3
Placebo35

Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period

Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event. (NCT00558259)
Timeframe: 6 months

InterventionParticipants (Number)
Dabigatran3
Placebo37

Centrally Confirmed Unexplained Deaths During the Intended Treatment Period

Number of participants with centrally confirmed unexplained deaths during the intended treatment period were described. (NCT00558259)
Timeframe: 6 months

Interventionparticipants (Number)
Dabigatran0
Placebo2

Centrally Confirmed Bleeding Event During the Treatment Period

"Major bleeding events (MBE) had to fulfil at least 1 of the following criteria:~Fatal bleeding~Associated with a fall in haemoglobin of ≥2 g/dL~Led to the transfusion of ≥2 units packed cells or whole blood~Occurred in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal~Other clinically relevant bleeding was defined as overt bleeding not meeting the criteria for an MBE but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.~Examples of these bleedings were:~Bleeding that compromised haemodynamics~Bleeding that led to hospitalisation~Trivial bleeding events were defined as all other bleeding events that did not fulfil the criteria of MBEs or CRBEs.~All bleeding events include MBEs, CRBEs, and trivial bleeding events." (NCT00558259)
Timeframe: 6 months

,
Interventionparticipants (Number)
MBEMBE or CRBEAll Bleeding
Dabigatran23672
Placebo01239

Laboratory Measures, Especially Liver Function Tests (LFTs)

Number of participants with possible clinically significant abnormalities during the treatment period. (NCT00558259)
Timeframe: 6 months

,
Interventionparticipants (Number)
AST increase (N=655, 629)ALT increase (N=655, 629)Alkaline phosphatase increase (N=658, 629)Total bilirubin increase (N=658, 628)
Dabigatran2301
Placebo2501

Laboratory Analyses

Frequency of patients with possible clinically significant abnormalities. (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout

,
Interventionparticipants (Number)
AST increaseAST decreaseALT increaseALT decreaseBilirubin increaseBilirubin decrease
Dabigatran 150 mg29031080
Warfarin27040060

Number of Participants Who Died (Any Cause)

Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg2529
Warfarin2526

Number of Participants Who Died Due to VTE

VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events. (NCT00680186)
Timeframe: From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg33
Warfarin00

Number of Participants With Acute Coronary Syndrome (ACS)

Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings. (NCT00680186)
Timeframe: From first intake of study drug to last contact date

,
Interventionparticipants (Number)
During intake of study drugAfter stopping study drug
Dabigatran 150 mg32
Warfarin01

Number of Participants With MBE, MBE and/or CRBE, and Any Bleeding Events

"Major bleeding events (MBE) are defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) are defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00680186)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout

,
Interventionparticipants (Number)
MBEMBE and/or CRBEAny bleeding event
Dabigatran 150 mg1564200
Warfarin22102285

Number of Participants With Recurrent Symptomatic DVT

Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg2528
Warfarin1717

Number of Participants With Recurrent Symptomatic Fatal and Non-fatal PE

Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg810
Warfarin1315

Number of Participants With Recurrent Symptomatic Non-fatal PE

Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg79
Warfarin1315

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE

All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg3034
Warfarin2830

Number of Participants With Recurrent Symptomatic VTE and All Deaths

VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00680186)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg5157
Warfarin4851

Composite of Recurrent VTE or All Cause Death at 18 Months

Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran361394
Warfarin321394

Composite of Recurrent VTE or All Cause Death at 36 Months

Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran421388
Warfarin361390

Composite of Recurrent VTE or VTE Death at 18 Months

Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran221408
Warfarin171409

Composite of Recurrent VTE or VTE Death at 36 Months

Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran261404
Warfarin181408

Deaths of All Causes at 18 Months

Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran151415
Warfarin161410

Deaths of All Causes at 36 Months

Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran171413
Warfarin191407

Deaths Related to VTE at 18 Months

Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran11429
Warfarin11425

Deaths Related to VTE at 36 Months

Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran11429
Warfarin11425

Deep Vein Thrombosis (DVT) at 36 Months

Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran171413
Warfarin131413

DVT at 18 Months

Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran151415
Warfarin121414

Laboratory Analysis

Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality). (NCT00329238)
Timeframe: 18 months + 30 days follow up

,
Interventionparticipants (Number)
ALT increaseAST increaseAlkaline phosphataseTotal bilirubin
Dabigatran262399
Warfarin3023148

Number of Participants With Bleeding Events

"MBE (major bleeding event) if it fulfilled at least one of the following criteria~Fatal bleeding~Symptomatic bleeding in a critical area or organ.~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.~Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs~CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria~Spontaneous skin haematoma ≥25 cm2~Spontaneous nose bleed >5 min duration~Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting >24 h~Spontaneous rectal bleeding~Gingival bleeding >5 min~Bleeding leading to hospitalisation or requiring surgical treatment~Bleeding leading to a transfusion of <2 units of whole blood or red cells~Any other bleeding event considered clinically relevant by the investigator" (NCT00329238)
Timeframe: first intake of study drug until 6 days following last intake of study drug

,
Interventionparticipants (Number)
patients with MBEpatients with MBE and /or CRBEpatients with any bleeding event
Dabigatran1380277
Warfarin25145373

Number of Participants With Definite Acute Coronary Syndrome (ACS)

All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner. (NCT00329238)
Timeframe: day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination

,
Interventionparticipants (Number)
During intake of study drug, N=1430 , N=1415After stopping study drug, N=1426, N=1400
Dabigatran121
Warfarin25

Symptomatic Pulmonary Embolism (PE) at 18 Months

Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 18 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran81422
Warfarin51421

Symptomatic Pulmonary Embolism (PE) at 36 Months

Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography. (NCT00329238)
Timeframe: 36 months

,
InterventionParticipants (Number)
Number of participants with eventNumber of participants with no event
Dabigatran101420
Warfarin51421

Laboratory Analyses

Frequency of patients with possible clinically significant abnormalities. (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)

,
Interventionparticipants (Number)
AST increaseAST decreaseALT increaseALT decreaseBilirubin increaseBilirubin decrease
Dabigatran 150 mg21026070
Warfarin220380130

Number of Participants Who Died (Any Cause)

Any deaths which occured from randomisation to end of post treatment period. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg2125
Warfarin2125

Number of Participants Who Died Due to VTE

"VTE - related deaths which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg11
Warfarin33

Number of Participants With Acute Coronary Syndrome (ACS)

"Any ACS occurring during the conduct of the study (centrally adjudicated as definite).~Counts of patients having a centrally adjudicated definite ACS during intake of active study drug, after stopping active study drug and before or without intake of active study drug, according to treatment group.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: From first intake of study drug to end of study conduct

,
Interventionparticipants (Number)
During intake of active study drugAfter stopping active study drugBefore/without intake of active study drug
Dabigatran 150 mg542
Warfarin320

Number of Participants With Bleeding Events

"Major bleeding events (MBE) were defined as~Fatal bleeding~Symptomatic bleeding in a critical area or organ~Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells~Clinically-relevant bleeding events (CRBE) was defined as~spontaneous skin hematoma >=25 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding (more than spotting on toilet paper)~gingival bleeding >5 min~leading to hospitalisation and / or requiring surgical treatment~leading to a transfusion of <2 units of whole blood or red cells~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00291330)
Timeframe: From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)

,
Interventionparticipants (Number)
Major bleeding eventsMBE and/or CRBEAny bleeding events
Dabigatran 150 mg2071207
Warfarin24111280

Number of Participants With Recurrent Symptomatic DVT

"Symptomatic DVT which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg1617
Warfarin1822

Number of Participants With Recurrent Symptomatic Non-fatal PE

"Symptomatic non-fatal PE which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
Interventionparticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg1316
Warfarin78

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE

All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)

,
InterventionParticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg3034
Warfarin2732

Number of Participants With Recurrent Symptomatic VTE and All Deaths

"VTE or any death which occured from randomisation to end of post treatment period.~All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee." (NCT00291330)
Timeframe: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.

,
InterventionParticipants (Number)
Participants with event (up to day 180)Participants with event (up to end of ptp)
Dabigatran 150 mg4855
Warfarin4453

Age Group

(NCT01428765)
Timeframe: Baseline

Interventionparticipants (Number)
<65 years65 to <75 years>= 75 years
All Patients382314367

Antithrombotic Treatment Choice at Baseline

(NCT01428765)
Timeframe: Baseline

Interventionparticipants (Number)
NoneVitamin K Antagonist (VKA)Acetylsalicylic Acid (ASA)Antiplatelet agents other than ASAOther
All Patients2153494433620

CHA2DS2-VASc Score

"The CHA2DS2-VASc risk score is based on a point system in which 2 points are assigned for a history of stroke or TIA, or age ≥75; and 1 point each is assigned for age 65-74 years, a hypertension, diabetes, cardiac failure, vascular disease and female sex. On the basis of the risk strata defined in previous guidelines, a CHA2DS2-VASc score of 0 corresponds to low risk, a score of 1 corresponds to intermediate risk, and a score of 2 or more corresponds to high risk." (NCT01428765)
Timeframe: Baseline

Interventionparticipants (Number)
Low (Score=0)Moderate (Score=1)High (Score >=2)
All Patients0226837

CHADS2 Score

CHADS2 score is based on a point system in which 2 points are assigned for a history of stroke or transient ischemic attack and 1 point each is assigned for age equal to or greater more than 75 years, hypertension, diabetes, or clinical heart failure or impaired left ventricular systolic function (generally interpreted as an ejection fraction ≤ 40%). (NCT01428765)
Timeframe: Baseline

Interventionparticipants (Number)
Low (Score=0)Moderate (Score=1)High (Score >=2)
All Patients102386575

Concomitant Medication

(NCT01428765)
Timeframe: Baseline

Interventionparticipants (Number)
Antihypertensive/heart failure and antiarrhythmicMetabolic and anti-inflammatory therapy
All Patients739395

Gender

(NCT01428765)
Timeframe: Baseline

Interventionparticipants (Number)
FemaleMale
All Patients486577

HAS-BLED Risk Score

The HAS-BLED score is based on a point system in which 1 point is assigned for hypertension (systolic blood pressure >160 mmHg), 1 point for each of abnormal renal (presence of chronic dialysis or renal transplantation or serum creatinine ≥200 μmol/L) and liver (chronic hepatic disease or biochemical evidence of significant hepatic derangement) function, 1 point each is assigned for stroke, bleeding (previous bleeding history and/or predisposition to bleeding), labile Internation Normalized Ratios (INRs,unstable/high INRs or poor time in therapeutic range), age >65 years and 1 point each for drugs (such as antiplatelet agents, non-steroidal anti-inflammatory drugs) or alcohol. (NCT01428765)
Timeframe: Baseline

Interventionparticipants (Number)
Low (Score <3)High (Score >=3)Missing
All Patients86012182

Medical History

(NCT01428765)
Timeframe: Baseline

Interventionparticipants (Number)
Previous strokeCoronary artery disease (CAD)Congestive heart failureHistory of hypertensionDiabetes mellitus
All Patients110256256795240

Incidence Rate of All-cause Death

Incidence rate of all-cause death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline2.08
Vitamin K Antagonist (VKA) - Baseline3.27

Incidence Rate of Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction, Life-threatening Bleeding Events and Vascular Death)

Incidence rate of composite outcome which includes events of Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. In case of multiple events for a patient, the first event was considered. Unknown death was imputed by multiple imputation. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline2.30
Vitamin K Antagonist (VKA) - Baseline3.02

Incidence Rate of Life-threatening Bleeding Events

Incidence rate of life-threatening bleeding events on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. Life-threatening bleeding was defined as meeting one or more of the following criteria: Symptomatic intracranial bleed; Reduction in haemoglobin of at least 50 grams per liter; Transfusion of at least 4 units of blood or packed cells, associated with hypotension requiring the use of intravenous inotropic agents; Necessitated surgical intervention; Fatal bleeding. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline0.50
Vitamin K Antagonist (VKA) - Baseline1.04

Incidence Rate of Major Bleeding Events

Incidence rate of major bleeding events on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. Major bleeding was defined as meeting one or more of the following criteria: Overt bleeding associated with a reduction in haemoglobin of at least 20 grams per liter or leading to a transfusion of at least 2 units of blood or packed cells; Symptomatic bleeding in a critical area or organ: Intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding or pericardial bleeding; Life-threatening bleeding. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline0.73
Vitamin K Antagonist (VKA) - Baseline1.42

Incidence Rate of Myocardial Infarction

Incidence rate of myocardial infarction on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline0.34
Vitamin K Antagonist (VKA) - Baseline0.45

Incidence Rate of Pulmonary Embolism (PE)

Incidence rate of pulmonary embolism (PE) on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline0.09
Vitamin K Antagonist (VKA) - Baseline0.06

Incidence Rate of Stroke

Incidence rate of stroke on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. Stroke is an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke included ischemic or hemorrhagic or uncertain classification. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline0.64
Vitamin K Antagonist (VKA) - Baseline0.96

Incidence Rate of Stroke or Systemic Embolism

Incidence rate of stroke or systemic embolism on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline0.69
Vitamin K Antagonist (VKA) - Baseline1.01

Incidence Rate of Systemic Embolism (SEE)

Incidence rate of systemic embolism (SEE) on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline0.07
Vitamin K Antagonist (VKA) - Baseline0.06

Incidence Rate of Transient Ischaemic Attack (TIA)

Incidence rate of transient ischaemic attack (TIA) on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline0.30
Vitamin K Antagonist (VKA) - Baseline0.26

Incidence Rate of Vascular Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction and Vascular Death)

Incidence rate of vascular composite outcome including events of stroke, systemic embolism, myocardial infarction and vascular death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. In case of multiple events for a patient, the first event was considered. Unknown death was imputed by multiple imputation. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline1.91
Vitamin K Antagonist (VKA) - Baseline2.36

Incidence Rate of Vascular Death

Incidence rate of vascular death on restricted set that included Dabigatran etexilate (DE) and Vitamin K Antagonist (VKA) only. (NCT01671007)
Timeframe: From baseline visit until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline0.76
Vitamin K Antagonist (VKA) - Baseline1.00

Incidence Rate of All-cause Death - Phase II

Incidence rate of all-cause death on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)2.48

Incidence Rate of All-cause Death - Phase III

Incidence rate of all-cause death on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)2.16
Vitamin K Antagonist (VKA) - Baseline (Phase III)3.57

Incidence Rate of Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction, Life-threatening Bleeding Events and Vascular Death) - Phase II

Incidence rate of composite outcome which includes events of Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only. In case of multiple events for a patient, the first event was considered. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)2.06

Incidence Rate of Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction, Life-threatening Bleeding Events and Vascular Death) - Phase III

Incidence rate of composite outcome which includes events of Stroke, systemic embolism, myocardial infarction, life-threatening bleeding events and vascular death on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. In case of multiple events for a patient, the first event was considered. Unknown cause of death was imputed by multiple imputation. Counts were based on the average of the 20 restricted data sets. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)2.21
Vitamin K Antagonist (VKA) - Baseline (Phase III)3.23

Incidence Rate of Life-threatening Bleeding Events - Phase II

Incidence rate of life-threatening bleeding events on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. Life-threatening bleeding was defined as meeting one or more of the following criteria: Symptomatic intracranial bleed; Reduction in haemoglobin of at least 50 grams per liter; Transfusion of at least 4 units of blood or packed cells, associated with hypotension requiring the use of intravenous inotropic agents; Necessitated surgical intervention; Fatal bleeding. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)0.46

Incidence Rate of Life-threatening Bleeding Events - Phase III

Incidence rate of life-threatening bleeding events on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. Life-threatening bleeding was defined as meeting one or more of the following criteria: Symptomatic intracranial bleed; Reduction in haemoglobin of at least 50 grams per liter; Transfusion of at least 4 units of blood or packed cells, associated with hypotension requiring the use of intravenous inotropic agents; Necessitated surgical intervention; Fatal bleeding. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)0.47
Vitamin K Antagonist (VKA) - Baseline (Phase III)1.07

Incidence Rate of Major Bleeding Events (MBE) - Phase II

Incidence rate of major bleeding events (MBE) on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. Major bleeding was defined as meeting one or more of the following criteria: Overt bleeding associated with a reduction in haemoglobin of at least 20 grams per liter or leading to a transfusion of at least 2 units of blood or packed cells; Symptomatic bleeding in a critical area or organ: Intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding or pericardial bleeding; Life-threatening bleeding. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)0.97

Incidence Rate of Major Bleeding Events (MBE) - Phase III

Incidence rate of major bleeding events on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. Major bleeding was defined as meeting one or more of the following criteria: Overt bleeding associated with a reduction in haemoglobin of at least 20 grams per liter or leading to a transfusion of at least 2 units of blood or packed cells; Symptomatic bleeding in a critical area or organ: Intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding or pericardial bleeding; Life-threatening bleeding. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)0.69
Vitamin K Antagonist (VKA) - Baseline (Phase III)1.44

Incidence Rate of Myocardial Infarction (MI) - Phase II

Incidence rate of myocardial infarction (MI) on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)0.50

Incidence Rate of Myocardial Infarction (MI) - Phase III

Incidence rate of myocardial infarction on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)0.40
Vitamin K Antagonist (VKA) - Baseline (Phase III)0.53

Incidence Rate of Pulmonary Embolism (PE) - Phase II

Incidence rate of pulmonary embolism (PE) on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)0.07

Incidence Rate of Pulmonary Embolism (PE) - Phase III

Incidence rate of pulmonary embolism (PE) on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)0.07
Vitamin K Antagonist (VKA) - Baseline (Phase III)0.06

Incidence Rate of Stroke - Phase II

Incidence rate of stroke on all eligible patients excluding prescribed but not taken set for Dabigatran etexilate (DE) of phase II only is presented. Stroke is an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke included ischemic or hemorrhagic or uncertain classification. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)0.65

Incidence Rate of Stroke - Phase III

Incidence rate of stroke on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. Stroke is an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke included ischemic or hemorrhagic or uncertain classification. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)0.77
Vitamin K Antagonist (VKA) - Baseline (Phase III)0.96

Incidence Rate of Stroke or Systemic Embolism - Phase III

Incidence rate of stroke or systemic embolism on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)0.80
Vitamin K Antagonist (VKA) - Baseline (Phase III)1.00

Incidence Rate of Systemic Embolism (SE) - Phase II

Incidence rate of systemic embolism (SE) on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)0.04

Incidence Rate of Systemic Embolism (SE) - Phase III

Incidence rate of systemic embolism (SE) on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)0.04
Vitamin K Antagonist (VKA) - Baseline (Phase III)0.05

Incidence Rate of Transient Ischaemic Attack (TIA) - Phase II

Incidence rate of transient ischaemic attack (TIA) on on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)0.21

Incidence Rate of Transient Ischaemic Attack (TIA) - Phase III

Incidence rate of transient ischaemic attack (TIA) on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)0.29
Vitamin K Antagonist (VKA) - Baseline (Phase III)0.32

Incidence Rate of Vascular Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction and Vascular Death) - Phase II

Incidence rate of vascular composite outcome including events of stroke, systemic embolism, myocardial infarction and vascular death on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only. In case of multiple events for a patient, the first event was considered. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)1.74

Incidence Rate of Vascular Composite Outcome (Stroke, Systemic Embolism, Myocardial Infarction and Vascular Death) - Phase III

Incidence rate of vascular composite outcome including events of stroke, systemic embolism, myocardial infarction and vascular death on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. In case of multiple events for a patient, the first event was considered. Unknown death was imputed by multiple imputation. Counts were based on the average of the 20 restricted data sets. The average of the 20 incidence rates from the 20 imputed datasets were used to obtain the point estimate of the incidence rate that is reported here. The bootstrapping approach was used to obtain the 95% confidence interval of the incidence rate. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)1.91
Vitamin K Antagonist (VKA) - Baseline (Phase III)2.62

Incidence Rate of Vascular Death - Phase II

Incidence rate of vascular death on all eligible patients excluding prescribed but not taken set that included Dabigatran etexilate (DE) of phase II only is presented. (NCT01468701)
Timeframe: From baseline visit of Phase II until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 2 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase II)0.85

Incidence Rate of Vascular Death - Phase III

Incidence rate of vascular death on restricted set that included Dabigatran etexilate (DE) of phase III and Vitamin K Antagonist (VKA) of phase III only. (NCT01468701)
Timeframe: From baseline visit of phase III until end of initial treatment regimen episode (minimum date of permanent stop of DE + 3 days/ VKA+ 6 days, start date of other treatments - 1 day, and date of study completion/discontinuation), up to 3 years.

InterventionEvents per 100 person-years (Number)
Dabigatran Etexilate - Baseline (Phase III)0.75
Vitamin K Antagonist (VKA) - Baseline (Phase III)1.26

Gaps Days Between Prescription Refills for Dabigatran, Rivaroxaban, and Apixaban

The investigators will calculate the # of gap days between refills for dabigatran/rivaroxaban/apixaban for each3 and 6 months of the pilot intervention. This will be based on pharmacy refill data and calculated using the date dabigatran/rivaroxaban/apixaban was dispensed and the # of days supplied for that prescription. We will add the # of gap days for each 3 and 6 months of the pilot for each patient, and compare the total # of gaps days between intervention and usual care patients. The gap days between refills is a validated measure of adherence and identifies patients with sub-optimal adherence.A negative gap day value indicates that participants received the refill prior to completion of the previous prescription. (NCT01578044)
Timeframe: 3 and 6 months

,
Interventiondays (Number)
# of Patient gap days for 3-months of intervention# of Patient gap days for 6-months of intervention
Intervention Group4341
Usual Care Group51-5

Apixaban Plasma Concentration, Cmax

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Interventionng/mL (Geometric Mean)
Apixaban 2.5 mg59.7
Apixaban 5 mg97.9

Apixaban Plasma Concentration, Cmin

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Interventionng/mL (Geometric Mean)
Apixaban 2.5 mg28.2
Apixaban 5mg49.7

Area Under the Plasma Apixaban Concentration Curve From 0 to 12 Hours After Dose (AUCO-12)

Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose

Interventionng*h/mL (Geometric Mean)
Apixaban 2.5 mg507
Apixaban 5mg868

Number of Participants Experiencing ISTH (International Society on Thrombosis and Haemostasis) Major or Clinically Relevant Non-major Bleeding

"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban21
Warfarin16

Number of Participants Experiencing Mortality

Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban21
Warfarin13

Number of Participants Experiencing Stroke

"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban2
Warfarin2

Number of Participants Experiencing Stroke or Systemic Embolism

Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban2
Warfarin2

Number of Participants Experiencing Stroke, Systemic Embolism, Major Bleeding or All-cause Mortality

"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban27
Warfarin29

Number of Participants Experiencing Systemic Embolism

"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionParticipants (Count of Participants)
Apixaban0
Warfarin0

Persistence of Therapy

Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit

InterventionDays (Mean)
Apixaban304.4
Warfarin279.6

Reviews

165 reviews available for beta-alanine and Atrial Fibrillation

ArticleYear
New anticoagulants in atrial fibrillation management.
    Thrombosis research, 2013, Volume: 131 Suppl 1

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-A

2013
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; bet

2013
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombin

2013
[The role of internal medicine in preventing stroke in atrial fibrillation].
    Medicina clinica, 2012, Volume: 139 Suppl 2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2012
[Advances in the secondary prevention of cardioembolic stroke].
    Medicina clinica, 2012, Volume: 139 Suppl 2

    Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindicatio

2012
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
    Drugs & aging, 2013, Volume: 30, Issue:7

    Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic

2013
[Improvements in oral anticoagulant therapy for atrial fibrillation].
    Medicina clinica, 2013, Dec-07, Volume: 141, Issue:11

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines;

2013
Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
    PharmacoEconomics, 2013, Volume: 31, Issue:7

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran;

2013
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
    International journal of clinical practice, 2013, Volume: 67, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini

2013
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
    Journal of medical economics, 2013, Volume: 16, Issue:7

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran

2013
[Direct oral thrombin inhibitor, "dabigatran"].
    Nihon rinsho. Japanese journal of clinical medicine, 2013, Volume: 71, Issue:1

    Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Contributions to nephrology, 2013, Volume: 179

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; C

2013
Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature.
    Neurosurgery, 2013, Volume: 73, Issue:2

    Topics: Accidental Falls; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Craniocere

2013
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
    Stroke, 2013, Volume: 44, Issue:6 Suppl 1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation

2013
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:24

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S

2013
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:7 Suppl

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological

2013
Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:7 Suppl

    Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine

2013
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2013, Volume: 16, Issue:4

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben

2013
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
    Heart failure reviews, 2014, Volume: 19, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug

2014
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
    Postgraduate medicine, 2013, Volume: 125, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines;

2013
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
    Reviews on recent clinical trials, 2013, Volume: 8, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
    JPMA. The Journal of the Pakistan Medical Association, 2013, Volume: 63, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines;

2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Clinical therapeutics, 2013, Volume: 35, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr

2013
Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Heart (British Cardiac Society), 2014, Volume: 100, Issue:4

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2014
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Neurologic clinics, 2013, Volume: 31, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig

2013
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
    Ideggyogyaszati szemle, 2013, May-30, Volume: 66, Issue:5-6

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2013
Novel oral anticoagulants: a review of new agents.
    Postgraduate medicine, 2013, Volume: 125, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S

2013
Novel oral anticoagulants in non-valvular atrial fibrillation.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini

2013
Novel oral anticoagulants in secondary prevention of stroke.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig

2013
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
    The Canadian journal of cardiology, 2013, Volume: 29, Issue:10

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
    Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:2

    Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis

2014
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.
    The American journal of cardiology, 2013, Dec-15, Volume: 112, Issue:12

    Topics: Amidines; Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamin

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
New oral anticoagulants--a review.
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2013, Oct-01, Volume: 133, Issue:18

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
    Polskie Archiwum Medycyny Wewnetrznej, 2013, Volume: 123, Issue:11

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ab

2013
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
    Journal of the American Heart Association, 2013, Oct-23, Volume: 2, Issue:5

    Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2013
Outpatient management of oral anticoagulation in atrial fibrillation.
    Critical care nursing clinics of North America, 2013, Volume: 25, Issue:4

    Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fact

2013
[Evidence of novel oral anticoagulants (NOAC)].
    Rinsho shinkeigaku = Clinical neurology, 2013, Volume: 53, Issue:11

    Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta

2013
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Journal of clinical pharmacy and therapeutics, 2014, Volume: 39, Issue:2

    Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Ca

2014
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
    Drug and therapeutics bulletin, 2014, Volume: 52, Issue:1

    Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Fact

2014
[New anticoagulants in patients with atrial fibrillation].
    MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Hum

2013
Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran.
    The American journal of cardiology, 2014, Mar-15, Volume: 113, Issue:6

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Global Health; Hemorrh

2014
New oral anticoagulants in practice: pharmacological and practical considerations.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:3

    Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comp

2014
[Novel oral anticoagulants and atrial fibrillation in the elderly].
    Geriatrie et psychologie neuropsychiatrie du vieillissement, 2013, Volume: 11, Issue:1 Suppl

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2013
Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials.
    Polskie Archiwum Medycyny Wewnetrznej, 2013, Volume: 123, Issue:11

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2013
Increased risk of myocardial infarction with dabigatran: fact or fiction?
    Journal of cardiovascular medicine (Hagerstown, Md.), 2014, Volume: 15, Issue:1

    Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2014
Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.
    The American journal of cardiology, 2014, Apr-01, Volume: 113, Issue:7

    Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr

2014
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
    Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzi

2014
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr

2014
Practical aspects of new oral anticoagulant use in atrial fibrillation.
    Polskie Archiwum Medycyny Wewnetrznej, 2014, Volume: 124, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2014
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2014, Volume: 29, Issue:3

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interaction

2014
Risk of major bleeding and the standard doses of dabigatran.
    European journal of internal medicine, 2014, Volume: 25, Issue:6

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ra

2014
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
    The Cochrane database of systematic reviews, 2014, Mar-27, Issue:3

    Topics: Amidines; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine

2014
Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.
    Drug safety, 2014, Volume: 37, Issue:5

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Risk Assessmen

2014
[Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature].
    Rinsho shinkeigaku = Clinical neurology, 2014, Volume: 54, Issue:3

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diffusion Magnet

2014
The newer direct oral anticoagulants: a practical guide.
    Clinical medicine (London, England), 2014, Volume: 14, Issue:2

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
Anticoagulation in atrial fibrillation.
    BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M

2014
Anticoagulation in atrial fibrillation.
    BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M

2014
Anticoagulation in atrial fibrillation.
    BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M

2014
Anticoagulation in atrial fibrillation.
    BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; M

2014
Anticoagulation: a GP primer on the new oral anticoagulants.
    Australian family physician, 2014, Volume: 43, Issue:5

    Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atri

2014
Management of anticoagulation around pacemaker and defibrillator surgery.
    Circulation, 2014, May-20, Volume: 129, Issue:20

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2014
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
    Current vascular pharmacology, 2014, Volume: 12, Issue:3

    Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine

2014
[Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: complex clinical situations and real clinical practice].
    Terapevticheskii arkhiv, 2014, Volume: 86, Issue:4

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hum

2014
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:3

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2014
[Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
    Kardiologiia, 2014, Volume: 54, Issue:2

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke

2014
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
    MMW Fortschritte der Medizin, 2014, Feb-06, Volume: 156, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen

2014
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
    The American journal of cardiology, 2014, Aug-15, Volume: 114, Issue:4

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2014
NOAC and intracerebral bleeding--presentation of four cases and review of the literature.
    Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, 2014, Issue:1

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabiga

2014
[Update on current care guideline: atrial fibrillation].
    Duodecim; laaketieteellinen aikakauskirja, 2014, Volume: 130, Issue:12

    Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Be

2014
[Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by new oral anticoagulants, to be cautiously used].
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2013, Volume: 80, Issue:4

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben

2013
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
    Cardiovascular & hematological disorders drug targets, 2014, Volume: 14, Issue:1

    Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discove

2014
Oral anticoagulants for stroke prevention in atrial fibrillation.
    Current problems in cardiology, 2014, Volume: 39, Issue:9

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2014
Target-specific oral anticoagulants: practice issues for the clinician.
    Hospital practice (1995), 2014, Volume: 42, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2014
Switching between oral anticoagulants.
    Hospital practice (1995), 2014, Volume: 42, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2014
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    International journal of clinical pharmacology and therapeutics, 2015, Volume: 53, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu

2015
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
    Orvosi hetilap, 2014, Oct-19, Volume: 155, Issue:42

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2014
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
    Nature reviews. Cardiology, 2014, Volume: 11, Issue:12

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors;

2014
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11

    Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles;

2014
Novel oral anticoagulants in non-valvular atrial fibrillation.
    Cardiovascular & hematological agents in medicinal chemistry, 2014, Volume: 12, Issue:1

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry,

2014
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?
    Hospital practice (1995), 2014, Volume: 42, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomedical Research; Dabigatran;

2014
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
    Lakartidningen, 2015, Jan-06, Volume: 112

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillat

2015
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Annual review of medicine, 2015, Volume: 66

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor

2015
[The use of dabigatran for prevention of ischemic stroke in patiets with atrial fibrillation: special features of treatment in different clinical situations].
    Kardiologiia, 2014, Volume: 54, Issue:9

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Secondary Pre

2014
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.
    American heart journal, 2015, Volume: 169, Issue:3

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2015
Overview of the new oral anticoagulants: opportunities and challenges.
    Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:5

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2015
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
    Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:16

    Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine;

2015
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation.
    Annals of hematology, 2016, Volume: 95, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; beta-Alanine; Clinical Decision-Making; D

2016
Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Cardiovascular therapeutics, 2010, Volume: 28, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; He

2010
Stroke in atrial fibrillation--hope on the horizon?
    Journal of the Royal Society, Interface, 2010, Dec-06, Volume: 7 Suppl 6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2010
Stroke prevention in the high-risk atrial fibrillation patient: Medical management.
    Current cardiology reports, 2011, Volume: 13, Issue:1

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2011
What's new in treating older adults?
    Cleveland Clinic journal of medicine, 2010, Volume: 77, Issue:11

    Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2010
Advances in the treatment of atrial fibrillation.
    Minerva cardioangiologica, 2010, Volume: 58, Issue:6

    Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; b

2010
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans;

2011
Atrial fibrillation in 2010: advances in treatment and management.
    Nature reviews. Cardiology, 2011, Volume: 8, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Co

2011
New anticoagulants: pharmacology and clinical studies.
    Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:3-4

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2011
Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management.
    Polskie Archiwum Medycyny Wewnetrznej, 2011, Volume: 121, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Co

2011
[Dabigatran, a new oral anticoagulant].
    Brain and nerve = Shinkei kenkyu no shinpo, 2011, Volume: 63, Issue:4

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2011
Frontiers of anticoagulation therapy for atrial fibrillation.
    Journal of cardiology, 2011, Volume: 58, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke

2011
New options for stroke prevention in atrial fibrillation.
    The American journal of managed care, 2010, Volume: 16, Issue:10 Suppl

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibito

2010
Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
    Advances in therapy, 2011, Volume: 28, Issue:6

    Topics: Age Factors; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Inte

2011
Atrial fibrillation: epidemiology, prognosis and therapy.
    Minerva medica, 2011, Volume: 102, Issue:3

    Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimida

2011
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Medecine sciences : M/S, 2011, Volume: 27, Issue:5

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr

2011
Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
    Neurosurgery, 2011, Volume: 68, Issue:2

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2011
Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2011
New anticoagulants for prevention of stroke in patients with atrial fibrillation.
    Journal of cardiovascular electrophysiology, 2011, Volume: 22, Issue:8

    Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Pyra

2011
[New concepts in the therapy of atrial fibrillation].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:31-32

    Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablati

2011
[The new Anticoagulants - Relevant Facts for the GP].
    Praxis, 2011, Aug-10, Volume: 100, Issue:16

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availab

2011
Stroke prevention in nonvalvular atrial fibrillation.
    Texas Heart Institute journal, 2011, Volume: 38, Issue:4

    Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Cathete

2011
[Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].
    Kardiologiia, 2011, Volume: 51, Issue:7

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Echo

2011
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
    Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:9

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine;

2011
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:5

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2011
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
    Current neurology and neuroscience reports, 2012, Volume: 12, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as

2012
[Atrial fibrillation: what the GP needs to know].
    MMW Fortschritte der Medizin, 2011, Sep-22, Volume: 153, Issue:38

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2011
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
    Journal of cardiothoracic and vascular anesthesia, 2011, Volume: 25, Issue:6

    Topics: Anesthesia, Conduction; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry

2011
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
    Critical pathways in cardiology, 2011, Volume: 10, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biopharmace

2011
A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices.
    Stroke, 2011, Volume: 42, Issue:11

    Topics: Animals; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2011
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Hospital practice (1995), 2011, Volume: 39, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Top

2011
Promise of factor Xa inhibition in atrial fibrillation.
    Current cardiology reports, 2012, Volume: 14, Issue:1

    Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fa

2012
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
    Kardiologiia, 2011, Volume: 51, Issue:11

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu

2011
Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Pharmacotherapy, 2011, Volume: 31, Issue:12

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International

2011
Stroke prevention in atrial fibrillation: do we still need warfarin?
    Current opinion in neurology, 2012, Volume: 25, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2012
Pharmacological basis and clinical evidence of dabigatran therapy.
    Journal of hematology & oncology, 2011, Dec-21, Volume: 4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Kidney Failur

2011
A new era of antithrombotic therapy in patients with atrial fibrillation.
    The American journal of the medical sciences, 2012, Volume: 344, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents;

2012
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
    Expert review of neurotherapeutics, 2012, Volume: 12, Issue:2

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors;

2012
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
    Cardiology journal, 2012, Volume: 19, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2012
A new generation of oral direct anticoagulants.
    Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:3

    Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimi

2012
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
    The neurologist, 2012, Volume: 18, Issue:2

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabi

2012
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2012, Volume: 18, Issue:5

    Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; b

2012
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire international, 2012, Volume: 21, Issue:124

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I

2012
Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Hu

2012
Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor

2012
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
    Journal of internal medicine, 2012, Volume: 271, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinica

2012
Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants.
    Circulation, 2012, Mar-27, Volume: 125, Issue:12

    Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da

2012
Dabigatran: a new chapter in anticoagulation.
    Cardiovascular & hematological agents in medicinal chemistry, 2012, Volume: 10, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2012
[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].
    Journal de pharmacie de Belgique, 2012, Issue:1

    Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-A

2012
[Pharmacological sheet. Dabigatran, oral administration (Pradaxa)].
    Journal de pharmacie de Belgique, 2012, Issue:1

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agent

2012
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    The American journal of cardiology, 2012, Aug-01, Volume: 110, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    The American journal of cardiology, 2012, Aug-01, Volume: 110, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    The American journal of cardiology, 2012, Aug-01, Volume: 110, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    The American journal of cardiology, 2012, Aug-01, Volume: 110, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr

2012
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
    MMW Fortschritte der Medizin, 2012, Mar-22, Volume: 154, Issue:5

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eviden

2012
[Prevention of cardioembolic stroke].
    Neurologia (Barcelona, Spain), 2012, Volume: 27 Suppl 1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Doubl

2012
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Advances in therapy, 2012, Volume: 29, Issue:6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tri

2012
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
    QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biologic

2012
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    International angiology : a journal of the International Union of Angiology, 2012, Volume: 31, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cereb

2012
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2012
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
    Journal of Zhejiang University. Science. B, 2012, Volume: 13, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C

2012
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
    Minerva cardioangiologica, 2012, Volume: 60, Issue:4

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2012
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
    Canadian family physician Medecin de famille canadien, 2012, Volume: 58, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Tech

2012
Challenges in atrial fibrillation.
    Advances in cardiology, 2012, Volume: 47

    Topics: Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, C

2012
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:4

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Stroke prevention in atrial fibrillation: concepts and controversies.
    Current cardiology reviews, 2012, Volume: 8, Issue:4

    Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzi

2012
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
    Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:9

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2012
What did we learn from new oral anticoagulant treatment?
    Thrombosis research, 2012, Volume: 130 Suppl 1

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; B

2012
Antithrombotic treatment of atrial fibrillation: new insights.
    Thrombosis research, 2012, Volume: 130 Suppl 1

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Kardiologia polska, 2012, Volume: 70, Issue:10

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2012
[Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation].
    Kardiologiia, 2012, Volume: 52, Issue:9

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coa

2012
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:18

    Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
[Stroke risk--atrial fibrillation].
    MMW Fortschritte der Medizin, 2012, Nov-01, Volume: 154, Issue:19

    Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sec

2012
The novel anticoagulants: the surgeons' prospective.
    Surgery, 2013, Volume: 153, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Tr

2013
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.
    Internal and emergency medicine, 2013, Volume: 8, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr

2013
A review of oral anticoagulants in patients with atrial fibrillation.
    Postgraduate medicine, 2012, Volume: 124, Issue:6

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morphol

2012
[Anticoagulant therapy in stroke patients].
    Ugeskrift for laeger, 2013, Jan-28, Volume: 175, Issue:5

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral He

2013
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
    The Journal of emergency medicine, 2013, Volume: 45, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emerge

2013
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Postgraduate medicine, 2013, Volume: 125, Issue:1

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013

Trials

28 trials available for beta-alanine and Atrial Fibrillation

ArticleYear
Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
    International journal of cardiology, 2013, Oct-03, Volume: 168, Issue:3

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Catheter Ablation; Comorb

2013
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Journal of the American College of Cardiology, 2013, Sep-03, Volume: 62, Issue:10

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Circulation, 2013, Jul-16, Volume: 128, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Circulation, 2013, Jul-16, Volume: 128, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Circulation, 2013, Jul-16, Volume: 128, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Circulation, 2013, Jul-16, Volume: 128, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2013
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
    European journal of heart failure, 2013, Volume: 15, Issue:9

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response R

2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Clinical therapeutics, 2013, Volume: 35, Issue:7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Dabigatran versus warfarin in patients with mechanical heart valves.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart V

2013
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study.
    Circulation, 2013, Nov-12, Volume: 128, Issue:20

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.
    Clinical drug investigation, 2013, Volume: 33, Issue:11

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrin

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Circulation, 2013, Nov-19, Volume: 128, Issue:21

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.
    Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, 2013, Volume: 20, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles;

2013
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Circulation, 2014, Mar-04, Volume: 129, Issue:9

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2014
Warfarin or dabigatran for treatment of atrial fibrillation.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:7

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Europe; Hemorrh

2014
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2014, Volume: 20, Issue:7

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, F

2014
Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:10

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Cont

2014
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2014, Volume: 37, Issue:221

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibi

2014
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
    Circulation, 2011, Jan-18, Volume: 123, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Tra

2011
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Ala

2011
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Circulation, 2011, May-31, Volume: 123, Issue:21

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alan

2011
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
    Annals of internal medicine, 2011, Nov-15, Volume: 155, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2011
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Circulation, 2012, Feb-07, Volume: 125, Issue:5

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzi

2012
[Expectation to and problems of thrombin inhibitor].
    Rinsho shinkeigaku = Clinical neurology, 2011, Volume: 51, Issue:11

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfar

2011
Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:3

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Respons

2012
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
    Stroke, 2012, Volume: 43, Issue:6

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans;

2012
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    European heart journal, 2013, Volume: 34, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben

2013
Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:10

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl

2012
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da

2013
A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
    Pacing and clinical electrophysiology : PACE, 2013, Volume: 36, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male;

2013

Other Studies

352 other studies available for beta-alanine and Atrial Fibrillation

ArticleYear
Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India.
    Value in health regional issues, 2022, Volume: 31

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran

2022
Questions in the comparative effectiveness of dabigatran and warfarin in atrial fibrillation.
    Journal of cardiology, 2017, Volume: 70, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin

2017
Dabigatran: Important Considerations in the Elderly.
    The Journal of emergency medicine, 2017, Volume: 52, Issue:6

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2017
Anticoagulation therapy: Uninterrupted dabigatran during ablation for AF.
    Nature reviews. Cardiology, 2017, Volume: 14, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin

2017
Osteoporotic Fractures Associated With Dabigatran vs Warfarin.
    JAMA, 2017, 07-04, Volume: 318, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic

2017
Osteoporotic Fractures Associated With Dabigatran vs Warfarin-Reply.
    JAMA, 2017, 07-04, Volume: 318, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic

2017
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
    The New England journal of medicine, 2017, 08-03, Volume: 377, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Hu

2017
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
    The New England journal of medicine, 2017, 08-03, Volume: 377, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Hu

2017
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
    The New England journal of medicine, 2017, 08-03, Volume: 377, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Hu

2017
Switching off the jitters: Dabigatran as a candidate approach to halt atrial fibrillation?
    International journal of cardiology, 2018, 11-15, Volume: 271

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Stroke; Warfar

2018
[Dabigatran as cause of severe gastrointestinal bleeding in a Jehovah's Witness patient].
    Ugeskrift for laeger, 2013, Feb-04, Volume: 175, Issue:6

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Critical

2013
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Hospital practice (1995), 2013, Volume: 41, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as

2013
Dabigatran overdose secondary to acute kidney injury and amiodarone use.
    The New Zealand medical journal, 2013, Mar-01, Volume: 126, Issue:1370

    Topics: Acute Kidney Injury; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fi

2013
Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.
    Critical care medicine, 2013, Volume: 41, Issue:5

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; C

2013
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
    Clinical cardiology, 2013, Volume: 36, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben

2013
Dabigatran: a nephrological way out.
    The American journal of medicine, 2013, Volume: 126, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Drug Approval; Humans; Stroke; Th

2013
The reply.
    The American journal of medicine, 2013, Volume: 126, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Drug Approval; Humans; Stroke; Th

2013
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
    Annals of emergency medicine, 2013, Volume: 61, Issue:4

    Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzi

2013
Acute pulmonary emboli in a patient on long-term dabigatran therapy.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:4

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans;

2013
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2013, Feb-15, Volume: 103, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
    Kardiologiia, 2013, Volume: 53, Issue:3

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C

2013
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Stroke, 2013, Volume: 44, Issue:6

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohor

2013
Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.
    Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:3

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confidence Intervals; Dabig

2013
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
    MMW Fortschritte der Medizin, 2013, Feb-21, Volume: 155, Issue:3

    Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel;

2013
Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
    Journal of cardiovascular electrophysiology, 2013, Volume: 24, Issue:8

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2013
Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 35, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; b

2013
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
    PharmacoEconomics, 2013, Volume: 31, Issue:7

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; He

2013
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
    Clinical pharmacology and therapeutics, 2013, Volume: 94, Issue:2

    Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular

2013
Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3

    Topics: Adult; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter A

2013
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
    Herz, 2013, Volume: 38, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
    The American journal of cardiology, 2013, Aug-01, Volume: 112, Issue:3

    Topics: Academic Medical Centers; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles;

2013
Periprocedural dabigatran in atrial fibrillation ablation: a new kid on the block.
    Journal of cardiovascular electrophysiology, 2013, Volume: 24, Issue:8

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
Dabigatran in clinical practice--one-year experience at Skåne University Hospital.
    Thrombosis research, 2013, Volume: 132, Issue:2

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans;

2013
Can dabigatran improve blood pressure control?
    Future cardiology, 2013, Volume: 9, Issue:3

    Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Antithrombins; Atrial Fib

2013
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
    American journal of respiratory and critical care medicine, 2013, Aug-15, Volume: 188, Issue:4

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analy

2013
Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
    Journal of cardiology, 2013, Volume: 62, Issue:2

    Topics: Age Factors; Aged; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fi

2013
Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran.
    Circulation. Cardiovascular imaging, 2013, May-01, Volume: 6, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Ec

2013
Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
    Circulation, 2013, Jun-18, Volume: 127, Issue:24

    Topics: Aged; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulation; Coro

2013
Placing a value on new technologies.
    Circulation, 2013, Jun-18, Volume: 127, Issue:24

    Topics: Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Occlusion; Dabigatran;

2013
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
    Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:9

    Topics: Accidental Falls; Acute Disease; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzim

2013
Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu

2014
New oral anticoagulants in atrial fibrillation forever?
    Circulation, 2013, Jul-16, Volume: 128, Issue:3

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Huma

2013
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:11

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Chromatog

2013
Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Jul-01, Volume: 70, Issue:13

    Topics: Adult; Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Calif

2013
Plasma dabigatran activity one week after discontinuation despite normal renal function.
    The American journal of medicine, 2013, Volume: 126, Issue:8

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastroin

2013
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2013
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabet

2013
Anticoagulation therapy: Dabigatran--a RELY-ABLE therapy?
    Nature reviews. Cardiology, 2013, Volume: 10, Issue:8

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Embolism; Female; Humans; Male; St

2013
"Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan.
    Journal of cardiology, 2013, Volume: 62, Issue:6

    Topics: Aged; Atrial Fibrillation; Attitude of Health Personnel; Benzimidazoles; beta-Alanine; Contraindicat

2013
Dental management considerations for a patient taking dabigatran etexilate: a case report.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2013, Volume: 116, Issue:3

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Or

2013
Adherence to anticoagulant treatment with dabigatran in a real-world setting.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; b

2013
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
    Circulation, 2013, Aug-13, Volume: 128, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2013
Reversal of dabigatran with haemodialysis in a patient requiring decompression for cord compression from an epidural abscess.
    Nephrology (Carlton, Vic.), 2013, Volume: 18, Issue:8

    Topics: Aged; Anti-Bacterial Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood

2013
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Journal of medical economics, 2013, Volume: 16, Issue:9

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben

2013
RE-LYing on dabigatran for periprocedural anticoagulation: is it safe?
    Pacing and clinical electrophysiology : PACE, 2013, Volume: 36, Issue:11

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Embolism

2013
Fatal association of mechanical valve thrombosis with dabigatran: a report of two cases.
    Chest, 2013, Volume: 144, Issue:1

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outcome; F

2013
Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 37, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.
    Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Thromboembo

2013
[New oral anticoagulants in nonvalvular atrial fibrillation].
    Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:9 Pt 1

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascu

2013
Should the newer oral anticoagulants be withheld from patients with valvular AF?
    Chest, 2013, Volume: 144, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases;

2013
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
    Journal of medical economics, 2013, Volume: 16, Issue:10

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analy

2013
Endovascular thrombectomy for acute ischemic stroke patients anticoagulated with dabigatran.
    Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:10

    Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia

2013
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Circulation. Cardiovascular quality and outcomes, 2013, Sep-01, Volume: 6, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2013
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
    Circulation, 2013, Aug-13, Volume: 128, Issue:7

    Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine

2013
[Differential therapy with the new anticoagulants, 5].
    MMW Fortschritte der Medizin, 2013, May-16, Volume: 155, Issue:9

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alani

2013
New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Irish medical journal, 2013, Volume: 106, Issue:3

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr

2013
The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran.
    Pacing and clinical electrophysiology : PACE, 2013, Volume: 36, Issue:11

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabig

2013
New oral anticoagulants in heart failure.
    European journal of heart failure, 2013, Volume: 15, Issue:9

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Failure

2013
Response to Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.
    Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Thromboembo

2013
Dabigatran and mechanical heart valves--not as easy as we hoped.
    The New England journal of medicine, 2013, Sep-26, Volume: 369, Issue:13

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve P

2013
Anticoagulation therapy: Results of RE-ALIGN disappoint.
    Nature reviews. Cardiology, 2013, Volume: 10, Issue:11

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2013
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
    Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2013, Volume: 72, Issue:9 Suppl 4

    Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta

2013
Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cereb

2014
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead.
    Heart (British Cardiac Society), 2014, Volume: 100, Issue:4

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperati

2014
Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; D

2014
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
    Clinical drug investigation, 2014, Volume: 34, Issue:1

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit

2014
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
    Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da

2014
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
    Circulation. Cardiovascular quality and outcomes, 2013, Volume: 6, Issue:6

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-

2013
New oral anticoagulants: an emergency department overview.
    Emergency medicine Australasia : EMA, 2013, Volume: 25, Issue:6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine;

2013
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:4

    Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular

2014
Dabigatran-induced upper intestinal bleeding in a patient with chronic kidney disease.
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2013, Nov-13, Volume: 33, Issue:6

    Topics: Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Mellitus,

2013
Evaluation of dabigatran utilization and risk among hospitalized patients.
    The Annals of pharmacotherapy, 2014, Volume: 48, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical

2014
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
    Journal of the American Heart Association, 2013, Nov-25, Volume: 2, Issue:6

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben

2013
Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy.
    Cardiovascular therapeutics, 2013, Volume: 31, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Isc

2013
New oral anticoagulants: their role and future.
    Clinical medicine (London, England), 2013, Volume: 13 Suppl 6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2013
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; D

2014
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead. The authors' reply.
    Heart (British Cardiac Society), 2014, Volume: 100, Issue:4

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperati

2014
ACP Journal Club. Dabigatran increased bleeding and stroke compared with warfarin after mechanical heart valve implantation.
    Annals of internal medicine, 2013, Dec-17, Volume: 159, Issue:12

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2013
Dabigatran use in mechanical heart valve patients.
    Future cardiology, 2014, Volume: 10, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation

2014
Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
    The American journal of medicine, 2014, Volume: 127, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2014
Dabigatran versus warfarin in patients with mechanical heart valves: comment.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
[Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery].
    Annales francaises d'anesthesie et de reanimation, 2014, Volume: 33, Issue:1

    Topics: Acute Kidney Injury; Aged, 80 and over; Alzheimer Disease; Antithrombins; Atrial Fibrillation; Benzi

2014
Dabigatran versus warfarin in patients with mechanical heart valves: reply.
    Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coa

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Dabigatran in patients with mechanical heart valves.
    The New England journal of medicine, 2014, 01-23, Volume: 370, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Novel anticoagulants in patients with mechanical heart valves.
    Evidence-based medicine, 2014, Volume: 19, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.
    The American journal of cardiology, 2014, Feb-15, Volume: 113, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da

2014
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Tr

2014
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Clinical therapeutics, 2014, Feb-01, Volume: 36, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefi

2014
Impaired renal function and bleeding in elderly treated with dabigatran.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2014
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    The American journal of medicine, 2014, Volume: 127, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2014
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:8

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cathe

2014
Massive haemoptysis following dabigatran administration in a patient with bronchiectasis.
    BMJ case reports, 2014, Feb-19, Volume: 2014

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Bronchial Arteries; Bronchie

2014
Dabigatran-induced lupus temporarily preventing blood group determination.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:6

    Topics: Aged, 80 and over; Anemia; Antibodies, Antinuclear; Antithrombins; Atrial Fibrillation; Benzimidazol

2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    American heart journal, 2014, Volume: 167, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr

2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    American heart journal, 2014, Volume: 167, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr

2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    American heart journal, 2014, Volume: 167, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr

2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    American heart journal, 2014, Volume: 167, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr

2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    American heart journal, 2014, Volume: 167, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr

2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    American heart journal, 2014, Volume: 167, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr

2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    American heart journal, 2014, Volume: 167, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr

2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    American heart journal, 2014, Volume: 167, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr

2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    American heart journal, 2014, Volume: 167, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cr

2014
Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
    The American journal of cardiology, 2014, Apr-15, Volume: 113, Issue:8

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benz

2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini

2014
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:1

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl

2014
Intracranial hemorrhage during dabigatran treatment.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2014
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
    PharmacoEconomics, 2014, Volume: 32, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben

2014
A case of dabigatran-associated acute renal failure.
    WMJ : official publication of the State Medical Society of Wisconsin, 2013, Volume: 112, Issue:4

    Topics: Acute Kidney Injury; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biopsy;

2013
[Hemodialysis to remove anticoagulant dabigatran during emergencies].
    Medicina, 2014, Volume: 74, Issue:2

    Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulati

2014
Self-management of vitamin K antagonists is more cost-effective than dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
    Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Stroke; Vit

2013
Self-management of vitamin K antagonists is more cost-effective than dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. Response.
    Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Stroke; Vit

2013
On the cost-effectiveness of dabigatran.
    Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Stroke; Vit

2013
On the cost-effectiveness of dabigatran. Response.
    Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Stroke; Vit

2013
Perioperative management of patients on new oral anticoagulants.
    The British journal of surgery, 2014, Volume: 101, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological

2014
A new class of powerful and informative simultaneous confidence intervals.
    Statistics in medicine, 2014, Aug-30, Volume: 33, Issue:19

    Topics: Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biosta

2014
New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients.
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:6

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intrac

2014
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Journal of medical economics, 2014, Volume: 17, Issue:8

    Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparati

2014
New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation.
    International journal of medical sciences, 2014, Volume: 11, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig

2014
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
    The American journal of medicine, 2014, Volume: 127, Issue:11

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
Direct oral anticoagulants in atrial fibrillation.
    Seminars in hematology, 2014, Volume: 51, Issue:2

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2014
Dabigatran in catheter ablation of atrial fibrillation: a call for a randomized control trial.
    The American journal of cardiology, 2014, Jun-15, Volume: 113, Issue:12

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans

2014
Good outcome after intravenous thrombolysis for acute stroke in a patient under treatment with dabigatran.
    The American journal of emergency medicine, 2014, Volume: 32, Issue:11

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; H

2014
The peri-procedural use of dabigatran in patients undergoing left atrial ablation for atrial fibrillation.
    Cardiovascular therapeutics, 2014, Volume: 32, Issue:5

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatra

2014
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St

2014
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St

2014
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St

2014
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
    American heart journal, 2014, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St

2014
[Dabigatran versus warfarin in patients with mechanical heart valves].
    Revista clinica espanola, 2014, Volume: 214, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; H

2014
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
    Clinical pharmacology and therapeutics, 2014, Volume: 96, Issue:1

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillat

2014
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
    Internal medicine journal, 2014, Volume: 44, Issue:6

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu

2014
Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.
    Stroke, 2014, Volume: 45, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2014
Atrial fibrillation choices. Picking an anti-clotting drug.
    Mayo Clinic health letter (English ed.), 2014, Volume: 32, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interaction

2014
Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.
    BMC health services research, 2014, Jul-17, Volume: 14

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillatio

2014
Treatment of atrial fibrillation.
    The Medical letter on drugs and therapeutics, 2014, Jul-07, Volume: 56, Issue:1446

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2014
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2014
Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation.
    Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:1

    Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2015
Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.
    The American journal of cardiology, 2014, Sep-15, Volume: 114, Issue:6

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabig

2014
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
    The American journal of medicine, 2014, Volume: 127, Issue:12

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2014
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
    Heart, lung & circulation, 2015, Volume: 24, Issue:1

    Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies

2015
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
    Harvard men's health watch, 2014, Volume: 18, Issue:9

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic A

2014
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:10

    Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles

2014
ACP Journal Club. In atrial fibrillation, dabigatran had similar efficacy to warfarin but caused less bleeding in higher GFR.
    Annals of internal medicine, 2014, Aug-19, Volume: 161, Issue:4

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Kidney; Male; Warfarin

2014
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
    Journal of medical economics, 2014, Volume: 17, Issue:11

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health

2014
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
    Stroke, 2014, Volume: 45, Issue:10

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans;

2014
Letter by Seitz and Beurtheret regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing risk analysis from the randomized evaluation of long-term anticoagulant therapy study".
    Circulation, 2014, Aug-26, Volume: 130, Issue:9

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ma

2014
Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study".
    Circulation, 2014, Aug-26, Volume: 130, Issue:9

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ma

2014
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
    Thrombosis research, 2014, Volume: 134, Issue:4

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Chr

2014
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
    Annals of medicine, 2014, Volume: 46, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Top

2014
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Kardiologiia, 2014, Volume: 54, Issue:7

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu

2014
Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    The American journal of medicine, 2014, Volume: 127, Issue:12

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al

2014
Monitoring of anticoagulant effects of dabigatran in everyday practice: first experience in 32 Polish patients.
    Polskie Archiwum Medycyny Wewnetrznej, 2014, Volume: 124, Issue:9

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring;

2014
Letter by Hifumi et al regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
    Circulation, 2014, Sep-02, Volume: 130, Issue:10

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe

2014
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
    Circulation, 2014, Sep-02, Volume: 130, Issue:10

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboe

2014
Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation.
    Journal of the American Heart Association, 2014, Sep-16, Volume: 3, Issue:5

    Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac S

2014
[Eligibility for dabigatran therapy: the real-life experience of a Tuscany general hospital].
    Recenti progressi in medicina, 2014, Volume: 105, Issue:9

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2015, Volume: 17, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; be

2015
Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
    The American journal of emergency medicine, 2014, Volume: 32, Issue:11

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; H

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
    The Canadian journal of cardiology, 2014, Volume: 30, Issue:10

    Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2014
Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding.
    British journal of haematology, 2015, Volume: 168, Issue:6

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Case-Control St

2015
Myocardial ischemic events in 'real world' patients treated with dabigatran.
    The American journal of medicine, 2014, Volume: 127, Issue:10

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ma

2014
The reply.
    The American journal of medicine, 2014, Volume: 127, Issue:10

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ma

2014
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
    Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit A

2014
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
    Circulation, 2014, Oct-21, Volume: 130, Issue:17

    Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials

2014
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
    BMC family practice, 2014, Oct-25, Volume: 15

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2014
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
    DukeMedicine healthnews, 2014, Volume: 20, Issue:9

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug E

2014
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Circulation, 2015, Jan-13, Volume: 131, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles

2015
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Circulation, 2015, Jan-13, Volume: 131, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles

2015
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Circulation, 2015, Jan-13, Volume: 131, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles

2015
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Circulation, 2015, Jan-13, Volume: 131, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles

2015
The importance of postapproval data for dabigatran.
    JAMA internal medicine, 2015, Volume: 175, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female

2015
Risk of bleeding with dabigatran in atrial fibrillation.
    JAMA internal medicine, 2015, Volume: 175, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz

2015
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 41, Issue:3

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbid

2014
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
    Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11

    Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alani

2014
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
    Stroke, 2015, Volume: 46, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Huma

2015
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
    Stroke, 2015, Volume: 46, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2015
Letter by Chin et al regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analy
    Circulation, 2014, Nov-25, Volume: 130, Issue:22

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Kidney; Male; Warfarin

2014
Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysi
    Circulation, 2014, Nov-25, Volume: 130, Issue:22

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Kidney; Male; Warfarin

2014
Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
    Nature reviews. Nephrology, 2015, Volume: 11, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy.
    The American journal of cardiology, 2015, Jan-01, Volume: 115, Issue:1

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Humans; Ischemic Attack, Trans

2015
CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
    Thrombosis research, 2015, Volume: 135, Issue:1

    Topics: Adolescent; Adult; Aged; Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazo

2015
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2014, Volume: 20, Issue:4

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coa

2014
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
    American heart journal, 2015, Volume: 169, Issue:1

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors;

2015
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cathe

2015
Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2015, Volume: 16, Issue:2

    Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Humans; M

2015
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
    Journal des maladies vasculaires, 2015, Volume: 40, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2015
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
    Circulation, 2015, Mar-17, Volume: 131, Issue:11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2015
Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.
    Nature reviews. Gastroenterology & hepatology, 2015, Volume: 12, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
[Fewer strokes, lower mortality. Large general practice studies confirm good safety profile of dabigatran].
    MMW Fortschritte der Medizin, 2014, Dec-15, Volume: 156, Issue:21-22

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2014
[Dabigatran and risk of bleeding].
    Praxis, 2015, Jan-28, Volume: 104, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose.
    DukeMedicine healthnews, 2014, Volume: 20, Issue:1

    Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Mo

2014
Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
    Stroke, 2015, Volume: 46, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra

2015
Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
    Stroke, 2015, Volume: 46, Issue:3

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracra

2015
Defining non-valvular atrial fibrillation while selecting anticoagulation therapy.
    British journal of hospital medicine (London, England : 2005), 2015, Volume: 76, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases;

2015
Patterns of oral anticoagulants use in atrial fibrillation.
    Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, 2015, Volume: 22, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Se

2015
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
    The American journal of cardiology, 2015, Mar-01, Volume: 115, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada;

2015
[Exfoliative esophagitis while taking dabigatran].
    Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Antithrombins; Atrial Fibrillation

2015
Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin.
    Evidence-based medicine, 2015, Volume: 20, Issue:3

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ischemic Attack, T

2015
Site-level variation in and practices associated with dabigatran adherence.
    JAMA, 2015, Apr-14, Volume: 313, Issue:14

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dab

2015
Contact with pharmacist can improve adherence to new anticoagulant, study finds.
    BMJ (Clinical research ed.), 2015, Apr-14, Volume: 350

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Drug Monitoring; Female; Humans; M

2015
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Circulation, 2015, Apr-21, Volume: 131, Issue:16

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindic

2015
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    BMJ (Clinical research ed.), 2015, Apr-24, Volume: 350

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort S

2015
Safety of new oral anticoagulants.
    BMJ (Clinical research ed.), 2015, Apr-24, Volume: 350

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha

2015
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
    BMJ (Clinical research ed.), 2015, Apr-24, Volume: 350

    Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2015
Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
    The American journal of cardiology, 2015, Jun-15, Volume: 115, Issue:12

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatra

2015
[Periprocedural management of anticoagulation in patients undergoing atrial fibrillation ablation].
    Revue medicale suisse, 2015, Mar-04, Volume: 11, Issue:464

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Hu

2015
Anticoagulation therapy: Bleeding no worse with novel agents.
    Nature reviews. Cardiology, 2015, Volume: 12, Issue:7

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha

2015
Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:10

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr

2015
[Prevention and emergency measures].
    MMW Fortschritte der Medizin, 2015, Apr-16, Volume: 157, Issue:7

    Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Hu

2015
[Advantages of NOAKs validated in clinical routine].
    MMW Fortschritte der Medizin, 2015, May-13, Volume: 157, Issue:9

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; G

2015
Effective antidotes for new anticoagulants.
    BMJ (Clinical research ed.), 2015, May-26, Volume: 350

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha

2015
Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition.
    International heart journal, 2015, Volume: 56, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabig

2015
Meta-analysis should not be subject to selectivity and imbalance.
    BMJ (Clinical research ed.), 2015, Jun-24, Volume: 350

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha

2015
One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Bleeding in Patients of African Ancestry Using Dabigatran: A Potential Effect of Creatine Kinase.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.
    JAMA internal medicine, 2015, Volume: 175, Issue:7

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage

2015
Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin.
    Annals of internal medicine, 2015, Sep-15, Volume: 163, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrha

2015
Letter by Lavine Regarding Article, "Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation".
    Circulation, 2015, Oct-06, Volume: 132, Issue:14

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Medicare; War

2015
Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation.
    Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfa

2015
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
    BMJ (Clinical research ed.), 2016, 10-03, Volume: 355

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2016
[Advances in the prevention of cerebral ischaemia due to atrial fibrillation].
    Neurologia (Barcelona, Spain), 2010, Volume: 25, Issue:7

    Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Benzimidazoles; beta-Alani

2010
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Annals of internal medicine, 2011, Jan-04, Volume: 154, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben

2011
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini

2011
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
    Circulation, 2011, Mar-15, Volume: 123, Issue:10

    Topics: Advisory Committees; American Heart Association; Anticoagulants; Antithrombins; Atrial Fibrillation;

2011
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
    Heart rhythm, 2011, Volume: 8, Issue:3

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Fibrinolytic

2011
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
    Journal of the American College of Cardiology, 2011, Mar-15, Volume: 57, Issue:11

    Topics: Advisory Committees; American Heart Association; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2011
[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
    Revista clinica espanola, 2011, Volume: 211, Issue:3

    Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles

2011
Next generation anticoagulants may push warfarin to the wayside.
    Managed care (Langhorne, Pa.), 2011, Volume: 20, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug E

2011
New drug offers warfarin alternative for atrial fibrillation. An immediate switch is right for some people, but not necessary for all.
    Harvard heart letter : from Harvard Medical School, 2011, Volume: 21, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug and Narcotic Con

2011
Place of dabigatran in contemporary pharmacotherapy.
    Pharmacotherapy, 2011, Volume: 31, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2011
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emboli

2011
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Annals of internal medicine, 2011, Apr-19, Volume: 154, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran

2011
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Annals of internal medicine, 2011, Apr-19, Volume: 154, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran

2011
Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:8

    Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2011
Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:8

    Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomarkers; Chronic Disease

2011
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Circulation, 2011, Jun-07, Volume: 123, Issue:22

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefi

2011
Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
    International journal of cardiology, 2012, Jan-26, Volume: 154, Issue:2

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Thrombosis; Dabiga

2012
Ask the doctor. For several years, I have been taking warfarin because of atrial fibrillation. I recently suffered several nosebleeds, which took two days to control. The trauma of those episodes makes me want to swear off warfarin, but I am not sure what
    Harvard health letter, 2011, Volume: 36, Issue:7

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Knowledge

2011
Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:7-8

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Femal

2011
Dabigatran in atrial fibrillation: pharmacology and clinical trials.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2011, Volume: 32, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2011
Atrial fibrillation: outpatient presentation and management.
    Circulation, 2011, Jul-05, Volume: 124, Issue:1

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-A

2011
Dabigatran in patients with nonvalvular atrial fibrillation.
    Journal of the American College of Cardiology, 2011, Jul-26, Volume: 58, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Dose-Resp

2011
New options in anticoagulation for atrial fibrillation.
    The New England journal of medicine, 2011, Sep-08, Volume: 365, Issue:10

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to

2011
New anticoagulants: moving on from scientific results to clinical implementation.
    Annals of medicine, 2011, Volume: 43, Issue:8

    Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzim

2011
A new era for anticoagulation in atrial fibrillation.
    The New England journal of medicine, 2011, Sep-15, Volume: 365, Issue:11

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines;

2011
Drug-induced exanthem following dabigatran.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:10

    Topics: Adult; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensi

2011
[New anticoagulants: "efficacy and safety" or "efficacy or safety"].
    Journal des maladies vasculaires, 2011, Volume: 36, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans

2011
Dabigatran for stroke prevention in all patients with atrial fibrillation?
    Pharmacotherapy, 2011, Volume: 31, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatr

2011
The use of dabigatran immediately after atrial fibrillation ablation.
    Journal of cardiovascular electrophysiology, 2012, Volume: 23, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2012
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:9

    Topics: Antithrombins; Area Under Curve; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulat

2012
Update on dabigatran for stroke prevention in atrial fibrillation.
    Connecticut medicine, 2011, Volume: 75, Issue:8

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2011
What's a mother to do?
    Journal of cardiovascular electrophysiology, 2012, Volume: 23, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Fe

2012
Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
    Annals of internal medicine, 2011, Nov-15, Volume: 155, Issue:10

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Fema

2011
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
    Journal of neurology, 2012, Volume: 259, Issue:1

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2012
[Anticoagulation in atrial fibrillation: a new era has begun].
    Hamostaseologie, 2012, Volume: 32, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines;

2012
Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 32, Issue:6

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Cerebrovascular Circulation;

2011
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort

2012
Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation.
    The American journal of emergency medicine, 2012, Volume: 30, Issue:9

    Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Fe

2012
Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:1

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Artery Bypass; Dabi

2012
Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
    Current medical research and opinion, 2012, Volume: 28, Issue:2

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II a

2012
Application of the RELY study to lifetime risks of atrial fibrillation: implications for spontaneous intracranial hemorrhage.
    Neurosurgery, 2012, Volume: 70, Issue:2

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intracranial H

2012
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
    International journal of stroke : official journal of the International Stroke Society, 2012, Volume: 7, Issue:2

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrha

2012
Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male;

2012
Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) tri
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male;

2012
Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Circulation, 2012, Jan-24, Volume: 125, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male;

2012
Anticoagulation for atrial fibrillation ablation: what is the optimal strategy?
    Journal of the American College of Cardiology, 2012, Mar-27, Volume: 59, Issue:13

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male;

2012
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Journal of the American College of Cardiology, 2012, Mar-27, Volume: 59, Issue:13

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatr

2012
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Stroke, 2012, Volume: 43, Issue:3

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefi

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Chest, 2012, Volume: 141, Issue:2 Suppl

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles;

2012
What's the "go to" anticoagulant for stroke prevention in atrial fibrillation?
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines;

2012
Monitoring of the effects of new-generation oral anticoagulants – what does it mean? – .
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:3

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Partial Thrombo

2012
Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:5

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Ev

2012
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
    Journal of the American College of Cardiology, 2012, Feb-28, Volume: 59, Issue:9

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relatio

2012
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Age and ageing, 2012, Volume: 41, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles;

2012
Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.
    Journal of neurosurgery, 2012, Volume: 116, Issue:5

    Topics: Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Hemorrhage, Traumatic; B

2012
Exfoliative esophagitis and esophageal ulcer induced by dabigatran.
    Endoscopy, 2012, Volume: 44 Suppl 2 UCTN

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Esophagitis; Es

2012
[Update on current care guidelines: atrial fibrillation].
    Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:4

    Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2012
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
    Journal of medical economics, 2012, Volume: 15, Issue:4

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Contro

2012
Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:4

    Topics: Acute Kidney Injury; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creati

2012
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
    Vascular and endovascular surgery, 2012, Volume: 46, Issue:4

    Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazole

2012
Avoiding adverse events with dabigatran by careful selection of eligible patients.
    The Medical journal of Australia, 2012, Apr-16, Volume: 196, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contr

2012
Endovascular therapy after stroke in a patient treated with dabigatran.
    The Medical journal of Australia, 2012, Apr-16, Volume: 196, Issue:7

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheterization; Cerebral A

2012
Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:8

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke

2012
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management.
    Wiener klinische Wochenschrift, 2012, Volume: 124, Issue:9-10

    Topics: Atrial Fibrillation; Austria; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Periop

2012
Intravenous thrombolysis in a stroke patient taking dabigatran.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cerebral Angio

2012
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
    The American journal of medicine, 2012, Volume: 125, Issue:8

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran;

2012
Letter by Freeman et al regarding article, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial".
    Stroke, 2012, Volume: 43, Issue:7

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; W

2012
[Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
    MMW Fortschritte der Medizin, 2012, Jan-19, Volume: 154, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug A

2012
An anticoagulation option for nonvalvular atrial fibrillation.
    The Journal of family practice, 2012, Volume: 61, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Tech

2012
[Prevention of stroke in atrial fibrillation].
    Neurologia (Barcelona, Spain), 2012, Volume: 27 Suppl 1

    Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra

2012
Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Angiography, Digital Subtraction; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine;

2012
Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antithrombins; Atrial Fibrillati

2012
Dabigatran for stroke prevention in atrial fibrillation.
    Hamostaseologie, 2012, Volume: 32, Issue:3

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicin

2012
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
    PloS one, 2012, Volume: 7, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran

2012
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
    European heart journal, 2012, Volume: 33, Issue:17

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Tech

2012
Letter by Stollberger and Finsterer regarding article, "intracranial hemorrhage in patients with atrial fibrillation during anticoagulation with Warfarin or Dabigatran: the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial".
    Stroke, 2012, Volume: 43, Issue:9

    Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; W

2012
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Top

2012
Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement; Atrial Fibrillation; Benzimidazol

2012
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini

2012
New anticoagulant fights for credibility.
    Managed care (Langhorne, Pa.), 2012, Volume: 21, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Formularies as Topic;

2012
New oral anticoagulant in atrial fibrillation: are they comparable?
    International angiology : a journal of the International Union of Angiology, 2012, Volume: 31, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Hum

2012
How country-specific should a country-specific cost-effectiveness analysis be?
    European heart journal, 2013, Volume: 34, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanin

2013
Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
    Journal of evaluation in clinical practice, 2013, Volume: 19, Issue:5

    Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eligibility De

2013
Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next?
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Top

2012
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
    Kardiologiia, 2012, Volume: 52, Issue:7

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo

2012
The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.
    Journal of thrombosis and thrombolysis, 2013, Volume: 35, Issue:1

    Topics: Aged, 80 and over; Anemia; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigat

2013
Agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:15

    Topics: Administration, Oral; Aged; Agranulocytosis; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillat

2012
Intravenous thrombolysis in a stroke patient taking dabigatran.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Fibrinolytic Agents; Humans; Infa

2013
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Abl

2012
Novel oral anticoagulants for stroke prevention in atrial fibrillation.
    European heart journal, 2012, Volume: 33, Issue:12

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:4

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic;

2012
Response to the letter by Lee et al.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Fibrinolytic Agents; Humans; Infa

2013
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
National trends in oral anticoagulant use in the United States, 2007 to 2011.
    Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atria

2012
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
    Revista espanola de cardiologia (English ed.), 2012, Volume: 65, Issue:10

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabi

2012
Dabigatran-induced acute hepatitis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2012, Volume: 18, Issue:5

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemical and Drug Induced Li

2012
Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
    Heart advisor, 2011, Volume: 14, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug I

2011
Safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation.
    Journal of the American College of Cardiology, 2012, Sep-18, Volume: 60, Issue:12

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Registries;

2012
Diffuse alveolar hemorrhage associated with dabigatran.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:18

    Topics: Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran;

2012
Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:3

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2012
Eligibility of patients with atrial fibrillation for new oral anticoagulants.
    International journal of cardiology, 2013, May-25, Volume: 165, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2013
Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2013, Volume: 14, Issue:9

    Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit

2013
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2013, Volume: 36, Issue:1

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation;

2013
Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data.
    Heart, lung & circulation, 2013, Volume: 22, Issue:1

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Da

2013
Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
    Cardiovascular journal of Africa, 2012, Volume: 23, Issue:6

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I

2012
[Antithrombotic prevention in atrial fibrillation: the new anticoagulant drugs].
    Giornale italiano di cardiologia (2006), 2012, Volume: 13, Issue:10 Suppl 2

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans

2012
New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants.
    Cardiovascular journal of Africa, 2012, Volume: 23, Issue:9

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigat

2012
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
    Clinical cardiology, 2012, Volume: 35, Issue:12

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hong Kon

2012
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
    Revista clinica espanola, 2012, Volume: 212 Suppl 1

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alani

2012
Periprocedural management and approach to bleeding in patients taking dabigatran.
    Circulation, 2012, Nov-13, Volume: 126, Issue:20

    Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatra

2012
Direct thrombin inhibitors: a case indicating benefit from 'plasmapheresis' in toxicity: a call for establishing "guidelines" in overdose and to find an "antidote"!
    American journal of therapeutics, 2012, Volume: 19, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antithrombins; Aspirin; Atrial Fibrillation; Ben

2012
Public health. Change of heart.
    The Health service journal, 2012, Jul-26, Volume: 122, Issue:6315

    Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Humans;

2012
Case study. Risk and reward.
    The Health service journal, 2012, Jul-26, Volume: 122, Issue:6315

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; England; Hospitals, P

2012
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles;

2013
[New anticoagulants: better knowledge, better prescriptions].
    Revue medicale suisse, 2012, Jan-18, Volume: 8, Issue:324

    Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eviden

2012
Benefits of dabigatran maintained for more than two years.
    Cardiovascular journal of Africa, 2012, Volume: 23, Issue:10

    Topics: American Heart Association; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain;

2012
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
    Prescrire international, 2012, Volume: 21, Issue:132

    Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fa

2012
Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.
    Heart rhythm, 2013, Volume: 10, Issue:4

    Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Control Studies; Cathe

2013
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
    Klinicheskaia meditsina, 2012, Volume: 90, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidaz

2012
Transitions of care in anticoagulation management for patients with atrial fibrillation.
    Hospital practice (1995), 2012, Volume: 40, Issue:4

    Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Ala

2012
Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland.
    Swiss medical weekly, 2013, Volume: 143

    Topics: Aged; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cos

2013
Australian MPs demand more data on dabigatran for atrial fibrillation.
    BMJ (Clinical research ed.), 2013, Jan-15, Volume: 346

    Topics: Antithrombins; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis;

2013
[Wünderlich syndrome in patient anticoagulated with dabigatran].
    Medicina clinica, 2013, Aug-17, Volume: 141, Issue:4

    Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia

2013
[Percutaneous left atrial appendage closure after resolution of left atrial appendage thrombi with dabigatran].
    Orvosi hetilap, 2013, Feb-17, Volume: 154, Issue:7

    Topics: Anticoagulants; Antithrombins; Atherectomy; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; b

2013